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Abstract 
This study is based on a proposal concerning the feasibility of using aliphatic tertiary 
amine N-oxides as antiarrhythmic agent prodrugs. Lignocaine was selected as a 
candidate for prodrug development, because the N-oxide is a non-active, polar 
derivative of lignocaine and the drug of choice for ventricular arrhythmia, a symptom 
associated with ischaemic episodes leading to regions of transiently hypoxic heart 
tissue. An HPLC analytical method was developed to study the metabolism of 
lignocaine N-oxide. The rapid and sensitive analysis of lignocaine and its metabolites 
was demonstrated with good reproducibility, stability and high recovery. In this 
study, it was identified that lignocaine N-oxide can be reduced to its active parent 
compound, lignocaine with no other metabolites detected in the absence of oxygen. 
Under anaerobic conditions, no further metabolism of lignocaine was demonstrated in 
rat liver microsomes and heart S9 fractions suggesting no secondary metabolites were 
formed. The reduction of lignocaine N-oxide has been shown to be both enzymic and 
non-enzymic, NADPH dependent, oxygen sensitive and can be suppressed by CO, 
CN- and protein denaturation. Under anaerobic conditions, in vitro lignocaine N-oxide 
reduction was found to occur in NADPH supplemented rat liver homogenates, 
microsomal suspensions; rat heart homogenates, cytosolic solutions; human 
phenotyped cytochrome P450 isoforms; purified enzymes- cytochrome P450 
reductase, xanthine oxidase, deoxymyoglobin and NADPHI ascorbate reduced 
protohaem (haemin). This reaction can be suppressed through the chemically 
mediated decrease ofP450 and bs levels in rat liver microsomes. Previous studies 
demonstrated that lignocaine N-oxide was non-active in aerobic rat heart in vivo and 
was potent under ischaemic conditions. In this study, high recovery of lignocaine 
N-oxide was found in the urine of normal rats suggesting low metabolism of the 
prodrug in oxic tissues. However, in hypoxic isolated rat hearts, lignocaine N-oxide 
was found to be reduced to lignocaine. The data presented suggested that the 
bioactivation of lignocaine N-oxide could be regulated by the prevailing oxygen 
tension in the ischaemic arrhythmic heart. Essentially the pro drug activation of 
lignocaine N-oxide may be triggered by the ischaemic state of the heart and 
terminated as the oxygen content in the heart returns to a more normal level. A 
controlled release and site-specific active drug delivery of lignocaine N-oxide, a 
hypoxia-mediated antiarrhythmic agent, may thus be achieved. 
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Chapter 1 Introduction 
1. 1 Hypoxia and oxygen mediated tissue damage 
1.1. 1 Hypoxia induced tissue injury 
Hypoxia is a common and serious aspect of many disease processes. It occurs in cells 
when there is a subnormal oxygen concentration. This may alter the cellular 
biochemical and physiological functions and produce pathological changes. 
In clinical practice, hypoxia occurs when the arterial oxygen pressure falls below the 
normal range of75 to 100 Torr. 1 Acute hypoxia can occur following an asthmatic 
attack, cardiac arrest, trauma, shock, stroke and carbon monoxide poisoning. 
Ischaemic damage due to acute hypoxia to the heart and brain results in high 
morbidity. Cardiovascular and pulmonary disorders, inflammation, chronic wounds 
and many other diseases which result in decreased blood flow and oxygen supply can 
produce chronic hypoxia which will cause damage to tissues and organs. 
Hypoxia alters cellular metabolism and cell functions. 1,2 There is inhibition of both 
oxygen dependent enzymic reactions and mitochondrial oxidative phosphorylation. 
These metabolic changes can lead to cell membrane dysfunction and progressive 
development of irreversible cell injury. Toxic cell injury can be observed in the 
morphologic, metabolic and genetic events involved and on the effect of altered ion 
homeostasis. Apoptosis, autophagocytosis, acidosis, ion deregulation and cell 
necrosis may occur and led to irreversible tissue damages. 
After hypoxia, reperfusion with oxygen can produce further tissue damage due to 
oxidative phosphorylation stopping, cellular ATP (adenosine triphosphate) levels 
dropping and increased concentrations of calcium and low molecular weight iron 
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complexes.3 Reperfusion injury of ischaemic tissue induces the generation of free 
radicals and other toxic oxygen species. Reactive oxygen species such as superoxide 
anions (02- -) and hydrogen peroxide may be important mediators of cell injury in the 
post-ischaemia reperfusion via the oxidation of membranes or the alteration of critical 
enzyme systems leading to pathophysiological disorders.4, 5 These reactive oxygen 
species play an important role in the pathology of cerebral ischaemia,6 irradiation 
damage,7 intestinal ischaemia,S inflammatorY and pulmonary disorders. 10 
Xanthine oxidase is reported to play an important role in ischaemia-reperfusion 
injury. Xanthine dehydrogenase can be converted into xanthine oxidase in ischaemic 
conditions and in the presence of the substrates hypoxanthine or xanthine. Xanthine 
oxidase will reduce molecular oxygen to O2- - and hydrogen peroxide that can be 
reduced further to the hydroxyl radical COH). During hypoxia, the process of 
hypoxanthine being converted to xanthine is triggered by the breakdown of A TP, 
ADP (adenosine diphosphate) to AMP (adenosine monophosphate), adenosine, 
inosine and finally to hypoxanthine.6, 11 Upon reperfusion, xanthine oxidase and its 
requisite substrates (hypoxanthine and/or xanthine) will be presented in high 
concentrations and consequently result in the formation of reactive oxygen species. 
The tissue damage can be inhibited by free radical scavengers, superoxide dismutase 
and catalase. The presence of xanthine oxidase inhibitors (e.g. allopurinol and its 
metabolite oxypurinol) can also decrease tissue damage indicating that xanthine 
oxidase generation of oxygen free radicals is a cause of ischaemic-reperfusion 









,J, adenosine deaminase 
mosme 
,J, nucleoside phosphorylase 
hypoxanthine 
O2 I xanthine dehydrogenase 
,J, I ,J, 
0/- ,J, xanthine oxidase 
xanthine 
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Scheme 1-1 Maj or pathways of adenosine nucleotide catabolism during myocardial 
ischaemia. 
1.1. 2 Cardiac hypoxia and tissue injury 
According to the World Health Organisation estimates in 1996, non-communicable 
diseases account for at least 40% of all deaths in developing countries and 75% in 
industrialised countries, where cardiovascular diseases are the first cause of 
mortality.I4 Myocardial arrhythmia among all cardiovascular diseases is the most 
frequent cause of the high morbidity and mortality. Although the immediate causes of 
such arrhythmias are often uncertain, a significant proportion have occurred after 
acute myocardial ischaemiaslhypoxias or infarction and can lead to "sudden cardiac 
deaths", particularly ventricular fibrillation. 15 
Myocardial ischaemia occurs because of a reduction in the coronary blood flow which 
is so severe that insufficient oxygen is delivered to prevent respiration shifting from 
aerobic to anaerobic. When ischaemia is of sufficient severity and persists long 
enough, so that myocytes become irreversibly injured and undergo cellular necrosis, 
the myocardial infarction occurs. As seen in Figure 1-1, oxygen deficiency induces 
metabolic changes, including decreased A TP, decreased pH, and lactate accumulation 
in ischaemic myocytes. The altered metabolic milieu leads to impaired membrane 
transport with resultant rearrangements in intracellular electrolytes. An increase in 





























(FFA & LPL releaseJ 
Impaired Membrane Integrity 
!!Calcium "AlP 
Irreversible Injury 
Figure 1-1 Postulated sequence of alterations involved in the pathogenesis of 
irreversible myocardial ischemic injury. 
From: Buja, LM Lipid abnormalities in myocardial cell injury. Trends 
Cardiovasc. Med. 1991, 1,40-45. 
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resultant cytoskeletal damage and impaired membrane phospholipid imbalance. Lipid 
alterations include increased phospholipid (PL) degradation with release of free fatty 
acids (FFA) and lysophospholipids (LPL), and decreased phospholipid synthesis. 
Lipid peroxidation occurs as a result of attack by free radicals produced at least in part 
by the generation of excess electrons (e-) in oxygen-deprived mitochondria. Free 
radicals also may be derived from metabolism of arachidonic acid and 
catecholamines, metabolism of adenine nucleotides by xanthine oxidase in 
endothelium (species dependent), and activation ofneutrophils and macrophages. The 
irreversible phase of injury appears to be mediated by severe membrane damage 
produced by phospholipid loss, lipid peroxidation, and cytoskeletal damage. 
Reperfusion of a heart subjected to either global or regional ischaemia may also 
produce active oxygen species and create myocardial damage. 16 Conditions of 
ischaemia and reperfusion can be seen during open heart procedures in cardiac 
surgery (e.g. cardiopulmonary bypass) and heart transplantation. It has been 
demonstrated that xanthine dehydrogenase is converted to xanthine oxidase and can 
induce myocardial reperfusion injury. I?, 18 
1.1. 3 Clinical treatment of myocardial hypoxia/ischaemia 
As cardiac arrhythmia is a major cause of death in patients with cardiac disease, it is 
evident that to control the incidence of sudden cardiac deaths, treatment should be 
directed primarily towards the prevention or suppression of the cardiac arrhythmia. 
Therefore, the administration of antiarrhythmic agents has become a major form of 
treatment in the management of cardiac arrhythmias. 
Various methods of classifying anti-arrhythmic agents have been employed although 
the most widely used classification of anti-arrhythmic drugs is that proposed by 
Vaughan Williams 19 and later modified by Harrison. 20 This classification is based 
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largely on in vitro electrophysiological effects of the drugs on myocardial cells. The 
action potential involved in the contraction of cardiac muscle consists of several 
phases controlled by ionic movements across the myocardial cell membrane. 
Class I agents include reagents which directly interfere with depolarisation of the cell 
membrane (membrane-stabilising agents) by blocking the fast inward current of 
sodium ions into cardiac cells; they also have local anaesthetic properties. They are 
subdivided into 3 further groups according to their effects on factors such as the 
duration of the cardiac action potential, the rate of change of the depolarisation phase 
of the cardiac action potential, the fibrillation threshold, conduction properties, and 
atrial and ventricular refractoriness. Class la drugs slow the rate of change of the 
depolarisation phase of the action potential, moderately prolong the repolarisation 
phase, and prolong the PR, QRS, and QT intervals on electrocardiogram (ECG) 
recordient. Typical agents of this class are disopyramide, procainamide and quinidine. 
Class Ib drugs have a limited effect on the rate of change of the depolarisation phase 
of the action potential, can shorten the repolarisation phase, shorten the QT interval, 
and elevate the fibrillation threshold. Typical agents of this class are lignocaine, 
mexiletine, phenytoin and tocainide. Class Ic drugs markedly slow the rate of change 
of the depolarisation phase of the action potential, have little effect on the 
repolarisation phase, and markedly prolong the PR and QRS intervals. Typical agents 
of this class are flecainide and propafenone. Class II drugs are the beta-adrenoceptor 
blocking agents. Class III drugs prolong the repolarisation phase of the action 
potential; amiodarone is a typical member of this class. Class IV drugs block the slow 
inward calcium current (calcium-channel blockers) although not all drugs that fall into 
the broad general category of calcium-channel blockers share the same specific 
properties; verapamil is a typical agent of this class. This classification system for 
anti-arrhythmic agents is summarised in Table 1-1. 
The precise diagnosis of the type of cardiac arrhythmia is a prerequisite for proper 
management. 21 The choice of therapeutic treatment is often varied due to different 
type of arrhythmias and the concern of potential toxicity or precautions from 
individual differences. This may be attributed to the narrow therapeutic index of the 
Chapter 1 Page 1-8 
Table 1-1 Classi fication and activity of antiarrhythmic agents 
Activity of AntI-arrhythmic Agents 
Effect on rate of change 
Effect on repolarisa-
of depolaris:lIlon phase 
lion phase of cardiac 
Beta-block- Calcium-channel 
of cardiac aCllon poten-
action potential 
ing activity blocking activity 
tial 
Class la 









flecamide Markedly ~Iow Lillie effect - -
propafenone 
Class II - - -
beta blockers + 
Class ill - - -
armodarone Prolong 
Class IV - - + -
verapamil 
from: Reynolds_ J. E. Martindale. The Extra Phannacopeia_ 30th ed._ 
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antiarrhythmic agents and the different pharmacokinetic/pharmacodymic properties of 
each individual (age, sex, disease, diet and other factors). In some instances, 
measurements such as pacing or direct current shock may be employed in addition to 
pharmacotherapy. The choices for antiarrhythmic agents in treating supraventricular 
arrhythmia and ventricular arrhythmia are listed in Table 1-2. Several types of drugs 
are effective in supraventricular arrhythmia. The main drugs used are amiodarone, 
disopyramide, procainamide, quinidine, verapamil and beta blockers (e.g. propanolol, 
atenolol). In ventricular tachyarrhythmias, including sustained ventricular tachycardia 
and ventricular arrhythmias following myocardial infarctions that warrant drug 
administration, lignocaine administered intravenously is the agent of choice.22 
Adverse side effects are commonly found to accompany the anti arrhythmia 
treatment. 23 There is, overwhelming evidence to suggest that many antiarrhythmic 
drugs can and do sometimes provoke or aggravate arrhythmias and do kill patients. 24, 
25, 26 In view of this, there is a need for new effective antiarrhythmic agents as most 
of the presently available drugs have limited efficacy, adverse side effects, 
inconvenient dosing regimes and interactions with other drugs. 
Furthermore, the main aim of clinical treatment of preventing recurrent myocardial 
ischaemic attack is not only to prevent the myocardial ischaemias but also to prolong 
the survival, free of stroke and myocardial infarction that leads to high mortality rates. 
Anticoagulant (e.g. heparin) and antiplatelet (e.g. aspirin, dipyridamole) drugs are 
used to reduce the risk of stroke. Surgical approaches (e.g. carotid endarterectomy and 
extracranial-to-intracranial bypass procedures) have been used to improve blood flow 
and oxygen supply to both heart and brain. Therefore, the quest for a safer and more 
effective antiarrhythmic agent is extremely important. 
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Table 1-2 
arrhythmias. 
Choice orantiarrhythmic agents in the treatment ofcardiac 
Choice of Anti-arrhythmic Agent 
Acute Alternatives for Long·term 
termination aClite termination suppression 
Supraventricular Arrhythmia Verapamil Amiodarone Amiodarone 





Atrial jlll(/er alld fihrillatioll Digoxin (til slow ven- Rela Rlocker or Bela Blocker 
tricular response) Verapamil (as addi- Digoxin 




At,.im'e/ll,-icltlar re-elllralll Adenosine Beta Blocker or Beta Blocker 
tac/rvcardia (pam.'fnmal Veraramil Disopyramide 
slipra\'/,/Ilricltlar wcilvcan/w) Quinidine 
Verapamil 
Ventricular Arrhythmia Lignocame Am lodarone Amiodarone 
(Phenytoin \lr Ligno- Bela £llocker £lela Blocker 
came if di!!oXIIl- Brerylium Di\opyrallude 





From: Reynolds, 1. E. Martindale, The Extra Pharmacopeia, 30ed., pp.57, The 
Phannaceutical Press, London, 1993 
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1.1. 4 Lignocaine 
Lignocaine, a local anaesthetic, is a class Ib agent and is used to control serious 
ventricular arrhythmias. It is the drug of choice for the treatment of ventricular 
premature beats, especially after acute myocardial infraction and is used parenterally 
for the acute treatment of arrhythmias that arises from cardiac surgery and 
catheterisation. It is also useful in the prevention of recurrence of ventricular 
fibrillation and to treat ventricular tachycardia. Lignocaine is used in treating 
digitalis-induced arrhythmias and heart failure, and has proved to be useful in the 
correction of those arrhythmias that persist despite administration of potassium and 
withdrawal of cardiac glycosides. 27, 28 
Lignocaine administration is limited to the parenteral route due to its rapid first pass 
metabolism in the liver. The most widely used regime for the administration of 
lignocaine consists of an intravenous bolus injection of 100 mg followed by a 
continuous infusion at 1-2 mg/min but this does not maintain plasma concentration in 
the therapeutic range. 29, 30 Therapeutic plasma concentration of lignocaine can be 
rapidly achieved and maintained by following the bolus injection with a constant 
infusion. Although it is highly effective and is extensively used in the clinic, 
lignocaine possesses dose-related side effects including dizziness, nausea, drowsiness, 
speech disturbances, beside numbness, muscle twitching, confusion, vertigo and/or 
tinnitus. Also, serious neurotoxicities such as sinus arrest, severe bradycardia or 
complete arterioventricular CAY) block may occur following lignocaine treatment.31 , 32 
Despite the above side effects, lignocaine has been the cornerstone of acute treatment 
for ventricular arrhythmias for nearly 20 years and there is yet no comparable drug for 
long tenn administration to treat established arrhythmias or prevent the development 
of arrhythmias. It has been demonstrated that lignocaine exerts its myocardial 
protective effect by scavenging highly cytotoxic reactive species of oxygen generated 
during ischaemia and reperfusion. This membrane stabilising property of lignocaine 
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can be attributed partially to its removal of hydroxyl radical and singlet oxygen that 
are implicated in membrane lipid peroxidation.30 
The metabolic fate of lignocaine has been studied extensively in experimental animals 
and humans.33, 34, 35, 36 In rat hepatic microsomes, lignocaine is sequentially 
N-deethylated to give first monoethylglycinexylidide (MEGX), and then glycine 
xylidide (GX). Both compounds were shown to possess antiarrhythmic activity and 
neurotoxicity. 37,38, 39, 40 Lignocaine is also metabolised via hydroxylation of the 
aromatic ring to give 3-or 4-hydroxylignocaine (3-0H-LIG or 4-0H-LIG), 
respectively.41, 42, 43 These reactions are catalysed by P450s in hepatic microsomes. 
Lignocaine and nine of its metabolites: MEGX, GX, 3-0H-LID, 4-0H-LIG, 
3-0H-MEGX, 4-0H-MEGX, 4-0H-GX, xylidine (XY) and 4-0H-XY, except 
lignocaine N-oxide, have been detected in human plasma and urine. 44 
1. 2 Prodrugs 
1.2. 1 Prodrug concept 
A prodrug is generally defined as a chemical which is pharmacodynamically inert and 
of low toxicity but which under physiological conditions may undergo spontaneous 
rearrangement or degradation or be converted enzymatically to a pharmacologically 
active drug. The prodrug concept has been recognised since the 1950'S45 and has 
. b . d . I 46 47 48 49 50 sInce een reviewe extensIve y. ' , , , 
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1.2.2 Prodrug approach 
A molecule with optimal structural configuration and physicochemical properties for 
achieving the desired therapeutic response at its target site does not necessarily 
possess the best molecular form and properties for its delivery to its point of ultimate 
action. A basic requisite for the prodrug approach to be useful in solving drug 
delivery problems is the ready availability of chemical moieties that satisfy the 
pro drug requirements. The most prominent of these is the reconversion of the 
prodrug to the parent drug in vivo. This pro drug-drug conversion may take place 
before absorption (i.e. in the gastrointestinal tract), during absorption, after absorption 
or at the specific site of drug action in the body, depending upon the specific purpose 
for which the pro drug is designed. Ideally, a pro drug should be converted into its 
parent compound in a controlled manner in order to achieve the highest efficacy and 
the lowest toxicity. Approaches to pro drug development have involved enhancement 
ofbioavailability and passage through various biological barriers, and increased site-
specificity. 
The conversion or activation of pro drugs to the parent drug molecules in the body can 
take place by a variety of reactions. The most common prodrugs are those requiring a 
hydrolytic cleavage mediated by enzymatic catalysis. Active drug species containing 
hydroxyl or carboxyl groups can often be converted into pro drugs from which the 
active forms are regenerated by esterases within the body. In other cases, active drug 
substances are regenerated from their pro drugs by biochemical reductive or oxidative 
processes. The application of bioreduction to the development of pro drugs of 
anticancer agents is described in the next section (1.2.3). 
1.2.3 Prodrug application: bioreductive anti-cancer agents 
Anticancer pro drugs have been synthesised to have more favourable physicochemical 
properties which may (a) increase the stability (b) optimise the route of 
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administration, (c) alter the distribution, (d) bypass drug resistance, (e) improve 
pharmacokinetics and (f) achieve selective activation in target cells. The approach of 
targeting bioreducing anticancer agents that are activated selectively by hypoxic 
tumour cells have been widely studied. 51,52,53,54 In chemotherapy, bioreductive 
pro drugs are activated by metabolic reduction in the hypoxic tumour cells to form 
highly effective cytotoxins. Tumour selectivity exploits the presence of hypoxia in 
tumours since oxygen can reverse the activating step of the bioreduction thereby 
greatly reducing the activity of the drug in most normal tissues. Molecular oxygen in 
cells acts principally as a terminal electron acceptor in oxidative phosphorylation and 
as a source of dioxygen for processes such as steroidogenesis and haem degradation. 
Flavoprotein based dehydrogenases and oxidoreductases mediate the flow of electrons 
from reducing equivalents in the form of the nicotinamide dinucleotide coenzymes, 
NADH and NADPH, to dioxygen and other endogenous acceptor molecules. Various 
chemotherapeutic agents are substrates for certain flavoprotein enzymes that 
ordinarily participate in intermediary metabolism. The selectivity depends on the 
level of expression of these particular enzymes in tumour cells for which the drug can 
act as a substrate. These include DT -diaphorase,55 various P450 isozymes,56, 57 
cytochrome P450 reductase58 and xanthine oxidase. 59, 60 Also, the enzymic 
expression in cells can be modulated by internal factors such as oxygen deficiency, 
intracellular pH changes, and even by the malignant phenotype itself. 
The bioreductive anticancer agents which have been extensively investigated fall into 
several subgroups predominantly the quinones, nitro compounds and N-oxides.61, 62 
The chemical structures of some bioreductive anti-tumour prodrugs are shown in 
Figure 1-2. Benzotriazene di-N-oxide (tirapazamine, SR4233t3 and the nitro 
compounds (RSU 1069 and RB 6145)64 are capable of killing hypoxic cells. The 
bioreductive mechanisms of qui nones (Diaziquone (AZQ), E09 and mitomycin C)65, 
66 relies on bioreductive activity of alkylating functional groups that crosslink DNA. 
However, there are major problems with these types of cytotoxic agents. First, they 
are likely to be dependent on chronic hypoxia to maintain activity since diffusion of 
the reactive species or parent compound away from the hypoxic tissue, or tissue 
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(b) E09 (e) RSlf 1069 
/ \ 
Ny N-CH2CH (OH)CH2NHCH2CH2Br 
o N02 
(c) mitomvcin C (f) RB 6145 
Figure 1-2 The chemical structures of some bioreductive anti-tumor prodrugs: (a) 
diaziquone (AZQ), (b) E09, (c) mitomycin C, (d) benzotriazene di-N-oxide 
(tirapazamine, SR4233), (e) RSU 1069 and (f) RB 6145. 
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reoxygenation will result in inactivity. Secondly, the intracellular target for most 
bioreductive agents is considered to be DNA and yet none of these agents accumulate 
in the nucleus since they do not possess specific, non-covalent DNA binding affinity. 
Also, although acute hypoxia in tumours could be a useful aspect of tumour 
physiology with regard to drug targeting, it would be advantageous if a bioreducibly 
activated agent could be developed that maintains activity even after oxygen 
reperfusion takes place. 
Aliphatic amine N-oxides with bioreductive potential and affinity of DNA binding 
have been developed as a new class of cytotoxic prodrugs. This concept is illustrated 
using the alkylaminoanthraquinones that are a group of cytotoxic agents with DNA 
binding affinity dependent on the cationic nature of these compounds.67 The actions 
of the alkylaminoanthraquinones involve drug intercalation into and inhibition of 
topoisomerase, an enzymes crucial to the processing of DNA prior to cell division. 
A di-N-oxide analogue of mitoxantrone, 1,4-bis([2-(dimethylamino-N-oxide) 
ethyl]amino) 5,8-dihydroxy anthracene-9,10-dione (AQ4N) has been shown to 
possess no intrinsic binding affinity for DNA, low toxicity and can be anaerobically 
reduced in vitro to its parent compound, 1, 4-bis([2-( dimethyl amino )-ethyl] amino )-
5,8-dihydroxyanthracene-9,10-dione (AQ4), with up to 1000 fold increase in 
cytotoxic potency (Figure 1-3). AQ4 is stable under oxic conditions. Studies indicate 
that the in vivo antitumour activity of AQ4N is manifest under conditions that 
promote transient hypoxia and/or diminish the oxic tumour fraction. The advantage 
of utilising the reductive environment of hypoxic tumours to reduce N-oxides is that 
unlike nitro or quinone based compounds, the resulting products will remain active 
even if the hypoxia that led to bioactivation is transient or the active compounds, once 
formed, diffuse away from the hypoxic tumour regions. Furthermore, the DNA 
affinic nature of the active compounds should ensure their localisation in tumour 
tissue. 68 The concept of using aliphatic amine N-oxides as hypoxic selective 
bioreductive pro drugs has been adapted in this project to study the hypoxiclischaemic 
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Figure 1-3 The bioreduction of 1,4-bis([2-(dimethylamino-N-oxide) ethyl] 
amino )5,8-dihydroxyanthracene -9,10- dione (AQ4N) to its parent compound, 
1,4-bis([2-(dimethylamino )-ethyl]amino )5,8-dihydroxyanthracene-9, 10-dione 
(AQ4). . 
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1. 3 Aliphatic tertiary amine N-oxides 
N-Oxides were discovered at the end of the last century. They are polar products of 
the two-electron oxidation of tertiary amines. Early this century the natural 
occurrence and, later on, the biological functions and interactions of N-oxides became 
known. The chemistry, pharmacology, biochemistry, toxicity~ and the possible use of 
amine N-oxides as therapeutic agents have been reviewed. 68, 69 Historical reviews of 
N-oxide formation by biological systems oxides have also been written.70, 71 
Many naturally occurring and synthetic N-oxides as well as N-oxide metabolites of 
amines have been reported to possess pharmacological activity72 or toxicity. Example 
of N-oxide which posses biological activity include (i) alkaloids, e.g. the N-oxides of 
strychnine, atropine, hyoscyamine, scopolamine and morphine (ii) chemotherapeutics, 
e.g. N-oxides of benzotriazines,73 and quinoxalines~ 74 (iii) antibiotics, e.g. iodinine 75 
and aspergillic acid;76 (iv) psychotropic drugs, e.g. chlordiazepoxide, active N-oxide 
metabolites of chlorpromazine and imipramine; (v) methemoglobin forming 
compounds, e.g. the N-oxide of N, N-dimethylaniline;77 and (vi) carcinogenic agents, 
e.g 4-nitroquinoline N-oxide,78 and indicine N-oxide, a pyrrolizidine alkaloid isolated 
from Heliotropium indicum, characterised as an antitumour agent and had been 
studied extensively.79 These amine N-oxides are either active themselves or can be 
reduced to their active parent compounds and may be categorised as "prodrugs". 
There are essentially four types of N-oxides: (a) tertiary aliphatic amine N-oxides, (b) 
N,N-dialkylarylamine N-oxides, (c) heteroaromatic N-oxides and (d) imino N-oxides 
(or nitrones). All these four classes of N-oxides (Figure 1-4) can be reduced to the 
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N-oxygenation of different types of tertiary amines to N-oxides. 
( a) tertiary amine N-oxide 
(b) N, N -dialkylarylamine N-oxide 
( c ) Heteroaromatic N-oxide 
(d) Imino N-oxides (nitrones) 
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1.3. 1 The formation of N-oxides: N-Oxidation 
Nitrogen-containing substances are the most common of all of organic compounds of 
pharmacological interest. Pharmacological or therapeutic interest in nitrogen-
containing compounds can be dated back to the application and toxicity studies of 
alkaloids and their extracts such as stimulants (cocaine, nicotine, caffeine), analgesic/ 
euphoriants (morphine), tranquilizers (reserpine) and decongestants (ephedrine). In 
spite of the extensive information on their pharmacology, the major pathways of 
metabolism were not thoroughly investigated until the mid-1950s. 
N-oxygenation is a common metabolism route of tertiary amines. The formation of 
N-oxides through N-oxygenation of tertiary amines involves the nitrogen lone pair of 
electrons. The metabolism of organic nitrogen compounds by N-oxidation was first 
described by Lintzel84 who reported that trimethylamine administered to humans was 
largely excreted as trimethylamine N-oxide. Subsequent studies with more complex 
amines showed that N-oxidation is a general route for metabolism of many nitrogen 
containing compounds; metabolites produced by an oxidative attack on a nitrogen 
centre are frequently detected both in vivo and in vitro. 85, 71 Interest in this pathway 
was further stimulated by the pioneering studies of the Millers 86 and Kiese87 on the 
role of N-oxidation in the metabolic activation of arylamides to more toxic and 
carcinogenic derivatives. 88 The chemistry and enzymology of oxidation of nitrogen 
. . d 89 90 91 92 compounds have been extenSIvely reVIewe . ' , , 
Nitrogen compounds may undergo N-oxygenation that includes N-hydroxylation and 
d d . N 'd 93 94 . I N-oxidation to form N-hydroxy compoun s an amme -OXl es,' respectIve y. 
N-Oxides may be formed as metabolites of drugs and other foreign compounds 
containing a tertiary aliphatic, tertiary alicyclic, N,N-dialkylaryl, or heteroaromatic 
. . ' 92 95 96 97 ammo functIOnahty. ' , , 
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Metabolic N-oxidation of tertiary amines has been generally considered to be 
catalysed by both flavin-containing monooxygenase98, 99 and the cytochrome P450 
system.
93 
Tertiary amines are N-dealkylated or N-oxygenated and the nature of the 
products formed is dependent on the structure of the amine as well as on the catalytic 
mechanism of the monooxygenases involved. lOo Lindeke and Cho proposed an 
N-oxidation followed by rearrangement to a-C-hydroxylation product as a possible 
mechanism for N-dealkylation.
91 
However, an N-oxide product has been 
demonstrated to be a major metabolite but not an obligatory intermediate in the 
dealkylation of tertiary amine. 101 Gorrod proposed a theory relating to the 
multiplicity of N-oxygenation enzymes and the pKa of nitrogen containing 
substrates. 95, 102 Less basic amines (less nucleophilic) were suggested to be better 
substrates for the cytochrome P450 dependent monooxygenase, whilst more basic 
amines were better substrates for the flavin containing monooxygenase. Exceptions 
exist but this hypothesis still serves as a basic principle in the determination of 
enzyme mediated amine oxidation pathways. 
1.3.2 Metabolism of tertiary amine N-oxides 
This study will concentrate on the reduction of tertiary aliphatic amine N-oxides. The 
. d' fr B' k I 85 103 h . d early systematic work on N-oXlde re uctlOn was om IC e,' w 0 summanse 
the complexities of this metabolic reaction. Essentially, N-oxide reduction has been 
reported to be enzymatic, non enzymatic or both~ aerobic or anaerobic~ heat-labile or 
heat-stable; dependent on, or not connected with xanthine oxidase; or dependent on 
various co-factors. 
Non-enzymic reduction of N-oxide has also been reported. Trimethylamine N-oxide 
can be reduced by Fe2+, cysteine, or reduced glutathione. 104 Similarly chlorpromazine 
N-oxide was reduced by Fe2+.105 Haem iron also had an effect on N-oxide reduction. 
The N-oxides of N,N-dimethylaniline, N,N-dimethylaminoazo-benzene and 
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imipramine are readily reduced in erythrocytes, or in oxygenated solutions of 
h 1 b· 101 106 Thi h . di . . aemog 0 In.' s aem-Iron me ated N-oXlde reductIOn may playa role in 
N-oxide metabolism in vivo. 
The studies by Dajani et al
lD7 
on nicotine-l I-N-oxide indicated the complex nature of 
the N-oxide reduction pathway. N-Oxide reduction was observed in both the soluble 
and the microsomal fraction of rat liver and small intestine, the reductase being non-
specific with regard to the requirement for NADH or NADPH. From various 
induction, inhibition and heat inactivation studies, Dajani concluded that nicotine-lI-
N-oxide reduction was mediated not only by cytochrome P450, but also linked 
partially to NADPH-dependent flavoprotein enzymes, such as NADPH-cytochrome 
P450 reductase or xanthine oxidase. 
The work done by Kato and co-workersI08, 109, 110 was the first that resulted in the 
clarification of the enzymology of aliphatic amine N-oxide reduction. Tertiary amine 
N-oxides were demonstrated to be reduced back to tertiary amines by rat liver 
subcellular preparations in the presence ofNADPH or NADH. Most of the reductase 
activity was located in the liver microsomal fraction. The microsomal NADPH 
dependent N-oxide reductase activity was inducible by phenobarbitone pre-treatment, 
oxygen sensitive, and inhibited by carbon monoxide, n-octylamine, 2,4-dichloro-6-
phenylphenoxyethylamine (DPEA) and various other P450 inhibitors, suggesting the 
involvement of cytochrome P450 in N-oxide reduction. Sugiura et at. 108 studied the 
combination ofNADPH and NADH on N-oxide reduction which prompted a closer 
investigation of the NADH-dependent N-oxide reductase activity. Iwasaki et al.
110 
have provided proof of the ability of cytochrome P450 to mediate N-oxide reduction. 
Studies with purified P450 have shown that both P450 and P448 will reduce tiaramide 
N-oxide at comparable rates, and that P450 isolated from rat, rabbit and Pseudomonas 
put ida had comparable reducing activity despite widely different substrate 
specificities in oxidation reactions. 
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Cytochrome P450 involvement has been further demonstrated in the case of indicine 
N-oxide reduction with rat liver microsomes by Powis.66 Indicine N-oxide is a 
pyrrolizidine alkaloid N-oxide with anticancer activity. Tiaramide N-oxide and 
indicine N-oxide reduction by rat hepatic microsomal fractions occurs under 
anaerobic conditions and is completely inhibited by carbon monoxide. However, in 
contrast to tiaramide N-oxide reduction, NADH is almost as effective as NADPH in 
supporting indicine N-oxide reduction. The NADH-dependent reduction is inhibited 
by potassium cyanide and by acetone, whereas the NADPH-dependent reduction is 
inhibited only slightly (3%) by potassium cyanide and stimulated by acetone. 
Phenobarbitone pre-treatment produces a selective increase in the maximal rate of the 
NADPH-dependent N-oxide reduction. Powis 66 rationalised these observations in 
terms of a different isoenzymic form of cytochrome P450 catalysing indicine N-oxide 
reduction, this isoenzyme being able to accept electrons from NADH to affect 
N-oxide reduction, but not contributing to oxidative microsomal drug metabolism. 
In addition to the microsomal reduction of N-oxide, the cytosol also appears to be a 
site for reduction of certain tertiary aliphatic amine N-oxides. A purified rat liver 
xanthine oxidase preparation was identified as being capable of the xanthine 
dependent reduction of benzyl amine N-oxide. 11 I The enzymic reduction seems to 
involve xanthine oxidase and! or cytochrome P450 in crude rat liver preparations. 
The N-oxide reduction was blocked by allopurinol, an inhibitor of xanthine oxidase, 
and n-octylamine, an inhibitor of cytochrome P450 N-oxide reductase. Johnson 
and Ziegler identified an NADPH-dependent cytosolic N-oxide reductase for 
N.N-dimethylaminoazo-benzene reduction. I 12 This protein was shown to be a 
cytosolic, NADPH-dependent N-oxide reductase. Although P450 and enzyme 
involvement in N-oxide reduction have been well recognised, their substrate 
specificities, mechanisms and their relative contributions to N-oxide reductions in 
vivo are still not fully known. 
The in vivo metabolism of N-oxides has not been studied extensively or 
systematically. Early studies on trimethylamine N-oxide suggested that N-oxide 
reduction of this compound is not a major route of metabolism. 84 The in vivo 
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metabolism of chlorpromazine N-oxide, amitriptyline N-oxide, indicine N-oxide and 
imipramine N-oxide have been reported to go through N-dealkylation, hydroxylation 
11 N ·d d . 113 114 115 116 . .. as we as -OXI e re uctlOn. ' " ZIegler proposed that tertIary ammes 
would undergo rapid N-oxidation in oxygenated tissues. 117 Thus, the concurrent 
occurrence of N-oxide reduction and N-oxidation makes the investigation of in vivo 
N-oxide reduction to its parent tertiary amine difficult. The reversible N-oxidation of 
these tertiary amines and their further oxidation! hydroxylation may be accounted for 
the absence of N-oxide reduction pathway in vivo. Although N-oxides may undergo 
in vivo reduction, a reversible oxidation!reduction may also occur and thus N-oxides 
may have long half-lives. 
N-oxides have been reported to undergo various non-enzymic rearrangements, i.e. 
Cope and Meisenheimer rearrangements. I 18 In the Cope rearrangement, tertiary 
amine N-oxides with f3 hydrogen atoms to the nitrogen decompose to secondary 
hydroxylamines and an alkene. The Meisenheimer rearrangement involves the 
migration of a group from nitrogen to oxygen in tertiary amine oxides having no f3 
hydrogen atoms. It has been reported that a tertiary amine N-oxide, pargyline 













These rearrangements may occur during the isolation of the metabolites. A similar 
rearrangement has been reported from studies on the metabolism of lignocaine. A 
cyclic metabolite, N1-ethyl-2-methyl-N3 -(2,6-dimethylphenyl)-4-imidazolidinone, 
attributed to reaction between monoethylglycinexylidide (MEGX) and ethanol has 
b ·d ·fi d 120 een I entl Ie . 
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Involvement of cytochrome p450 in tertiary amine 
N-oxide reduction 
In biological systems, compounds can undergo metabolism through oxidation or 
reduction of the nitrogen derivatives to form polar metabolites that are readily 
eliminated in the urine. The oxidation and reduction reactions can be catalyzed by the 
cytochrome P450 systems. The involvement of cytochrome P450 in metabolising 
tertiary amine N-oxide reduction is investigated in this study. 
1.3.3. 1 The cytochrome P450 enzymes 
Cytochrome P450 is a b-type haemoprotein that contains iron protoporphyrin IX as a 
prosthetic group, and exhibits an unusual absorption maximum at 450 nm for its 
ferrous carbon monoxide complex. 121,122 Cytochrome P450 can be found in plants, 
animals and microorganisms, and takes part in a great variety of biochemical 
oxidation/reduction reactions. Cytochrome P450 exists as multiple forms. 123, 124, 125 
Some including mitochondrial based steroid-hydroxylating and the bacterial 
cytochrome P450s are characterised by strict substrate specificity. Other isoforms are 
located in the liver microsomal fractions that possess a wide substrate specificity due 
to the existence of multiple cytochrome P450 isozymes, and hence can oxygenate 
non-polar substances of different chemical natures. By converting a hydrophobic 
compound into a more polar product, cytochrome P450 facilitates the elimination of 
non-polar molecules from the body. At least two proteins, NADPH-specific 
flavoprotein and cytochrome P450 haemoprotein, are necessary for the catalytic 
., . I d 126 127 128 129 Th acttVIty III the presence ofNADPH as an e ectron onor. ' " e 
flavoprotein reductase, contains both flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) prosthetic groups and functions in the transfer of reducing 
equivalents from NADPH to the cytochrome. 
. . 130 \31 132 133 
The various cytochrome P450 Isoforms have been claSSIfied by Nebert. ' , , 
The characteristic functions and properties of multiple forms of cytochrome P450 in 
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human and animals have been extensively studied and reviewed by Guengerich. 134, 
135 136 137 138 139 d··· .. , , , , In IVIdual dIfferences III the Isofonns of cytochrome P450 may be 
due to various factors such as race, sex, age, diet, disease, life style,140 as well as 
exposure to a variety of inducing or suppressing agents including drugs, chemicals, 
and carcinogens. 141, 142,143, 144, 145 
To date, more than 150 different cytochrome P450 forms have been identified. The 
recommended nomenclature system unambiguously identifies each form as a unique 
protein, based on the percentage homology of primary amino acid sequences. 
Proteins in the same cytochrome P450 family are at least 40% homologous and are 
greater than 55% in the cytochrome P450 subfamilies. When describing the 
cytochrome P450 gene, "CYP "is italicised and designates the gene for cytochrome 
P450. The first Arabic numeral designates the cytochrome P450 family. This is 
followed by a capital letter designating the subfamily, and another Arabic numeral to 
distinguish members within a subfamily. Cytochrome P450 isoform mediated 
enzymic reactions have been studied in many pathways of metabolism 146, 147 
e.g. CYPIA2 and CYP3A in imipramine N-oxygenation and C-hydroxylation
l48 
and 
N-hydroxylation of dapsone by cytochrome CYP3A4.149 
1.3.3.2 Mechanism of cytochrome P450 mediated oxidation and reduction 
The overall monooxygenase reaction catalysed by this system is: 
RH + NAD(P)H + O2 + H+ --» ROH + NAD(Pt + H20 
The mechanisms of the catalytic reactions of the cytochrome P450 enzymes have 
been extensively studied and characterised into several chemical steps (Figure 
1_5a).150 The process begins with the substrate binding to the ferric form of the 
cytochrome P450 enzyme. CDOxidised cytochrome P450 [Fe(III)] can react with a 
molecule of substrate (R) to form the enzyme-substrate complex. ® The P450-
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subtrate complex then undergoes a one electron reduction catalysed by NADPH 
dependent cytochrome P450 reductase. ® The resultant complex of the reduced 
(ferrous) haemoprotein and substrate [Fe(II)-R] can react with oxygen to form a 
ternary complex called oxycytochrome P450 (R-P450-02). @ A second electron than 
enters the complex. This electron can come from either NADPH dependent 
cytochrome P450 reductase or NADH cytochrome bs reductase. Following ® the 
protonation of the [Fe(II)-02+] complex and the release of one molecule of water, 
® the oxygenated [Fe(V)=O] or [Fe(III)-O] is then converted to [Fe (III)] and the 
formation of an oxidised substrate. CDThe series of cytochrome P450-directed 
reactions is concluded when the oxidised substrate dissociates from cytochrome P450, 
regenerating the ferric haemoprotein. The sequence of reactions described above has 
most of the common features for all types of cytochrome P450, regardless of source. 
Although cytochrome P450 is known predominantly as a mixed function oxidase, 
there is some evidence in the literature 1 10 that this haemoprotein can act as a reductase 
in the absence of oxygen. A two electron reaction mechanism was proposed earlier 
by Kato and Sugiura for the cytochrome P450 mediated tertiary amine N-oxide 
reduction steps (Figure 1-5 b) including imipramine N-oxide, tiaramide N-oxide and 
N,N-dimethylaniline N-oxide. 108 The reaction starts with a one electron reduction of 
cytochrome P450 via NADPH-cytochrome P450 reductase. The N-oxide substrate is 
directly co-ordinated to the reduced cytochrome haem. Followed by a further one 
electron reduction of the reduced cytochrome P450-N-oxide (substrate) complex, the 
tertiary amine N-oxide is reduced to give the corresponding tertiary amine and one 
molecule of water. 
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Figure 1-5 (a) Proposed catalytic cycle for reduction and oxidation of cytochrome 














Figure 1-5 (b) Proposed catalytic cycle for the reduction of tertiary amine 
N-oxides by liver microsomal cytochrome P450. (Sugiura, Iwasaki and Kato, 
1976) 
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1.3.3. 3 Type I and Type II binding of substrate to cytochrome P450 
In the presence of a cytochrome P450 enzyme system, certain electron-rich 
nitrogenous substrates, such as N-oxides, will form spectrally defined complexes. 
The substrate binding to cytochrome P450 induces some confonnational changes 
around the haem centre and increases the redox potential of the haem iron. 151 , 152 This 
binding often perturbs the P450 spectrum in the visible region causing a characteristic 
substrate-binding spectrum. A pronounced spectral characteristic of all porphyrin 
derivatives is that upon excitation they give rise to an intense 1t~ 1t * transition at 
about 400 nm (the Soret band), which is due to delocalization extending throughout 
the tetrapyrrole ring system, and some other characteristic longer wavelength bands. 
The spectral characteristics are sensitive to changes in the haemporphyrin as well as 
changes in its environment. Thus, changes in the haem iron oxidation states or spin 
(ligation) states of the iron atom can be distinguished as the conformational changes 
in the protein surrounding the haem group. 153 This inherent chromophoric property 
has made spectrophotometric methods a useful tool in analysing cytochrome P450 
. . 1 d· I b· d ·d 154 155 156 and other haemoprotems mc u mg myog 0 m an peroxI ases. ' , 
The most significant property of the haemoporphyrins is their capacity to bind 
molecular oxygen. This is the basis of oxygen transportation by myoglobin and 
haemoglobin as well as the activation of molecular oxygen by various cytochromes 
including cytochrome P450. Oxygen binding can occur only when the iron of the 
haem is in its reduced [Fe(II)] state. In cytochrome P450 mediated reactions, 
reduction of the haem iron of the enzyme-substrate complex generates a high-spin 
(pentacoordinated) ferrous form which is capable of binding oxygen. Upon the 
binding of oxygen, cytochrome P450 forms a low-spin (hexacoordinated) ferrous 
enzyme-substrate oxygen complex (Figure 1-6). The substrate-P450 complexes are 
b I·· d· I "(MI I ) 157 termed the "meta 0 IC mterme Iary comp ex comp exes . 
In studies of cytochrome P450-mediated reactions, there are two main types of 
spectral perturbations in the Soret region. These changes are classified as type I and 




Figure 1-6 Schemic reaction cycle of cytochrome P450, showing proposed 
ligand and spin state changes. (Lindeke, B., Paulsen-Sonnan, 1988). 
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type II spectral changes. Spectrally these two types of perturbations are essentially 
mirror images of each other and both result from the interaction of the enzyme in its 
oxidised (Fe3+) form with various substrates (Figure 1-7). Substrates have been 
classified as type I or type II depending on their ability to cause either type I or type II 
spectral changes upon addition to the enzyme. Type I spectral changes have been 
considered to be associated with metabolism, i.e. to be the optical manifestation of the 
binding of substrate to the protein moiety of the enzyme; while type II spectral 
perturbations are believed to reflect a direct interaction between the substrate and the 
haem iron. 
In the binding of nitrogenous compounds to ferric cytochrome P450, the type II 
spectral change, as characterised by an absorption peak at 425-435 nm and a trough at 
390-405 nm, has been shown to arise from ligand binding of nitrogen, in which sp2 or 
sp3 non bonded electrons are sterically accessible to the haem iron of cytochrome 
P450. The type I spectral change, as documented by the appearance of an absorption 
peak at 385-390 nm and an absorption minimum at 420 nm, is believed to arise from 
the displacement of the sixth haem ligand in the cytochrome P450 molecule through 
substrate binding to a hydrophobic domain in the apoprotein. 158, 159, 160, 161 
1.3.3. 4 The effect of cobalt on haem oxygenase and cytochrome P450 
Haem oxygenase is a microsomal enzyme which catalyses the NADPH-cytochrome 
P450 reductase dependent degradation of haem to biliverdin at the expense of three 
oxygen molecules. 162, 163 It is a monomeric protein that has a molecular weight in the 
range of 30 to 35kDa and exists as two isoenzymes- HO-1 and HO-2. 164 Early studies 
demonstrated that several metals, such as cobalt, tin, and cadmium could act as haem 
oxygenase inducers. 165, 166 Administration of cobalt was shown to increase the 
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Figure 1-7 (a) Aerobic difference spectra of liver microsomes with the iron in 
its oxidized (Fe"') state, in the presence ofN-hydroxyamphetamine (-= type 
II) and N-hydroxy-phentennine (---= type I). (b) Difference spectra ofliver 
microsomes with the iron in its reduced (Fe') state, in the presence of carbon 
monoxide. (Lindeke, B., Paulsen-Sorman, J 988). 
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enzyme activity of haem oxygenase with a decrease in the microsomal content of 
cytochrome P450.
167 
The characteristic, function, and isoforms of haem oxygenase 
has been extensively studied and reviewed by Maines. 168, 169 
Haem oxygenase has been identified as being decreased under various cellular 
stresses and disease states and is classified as an oxidative stress sensitive protein. 170 
In hypoxic cells, the increase in haem oxygenase activity provides protection for cells 
against oxidative stress. This situation is observed in tumour hypoxic conditions and 
heart and kidney ischaemias. 171, 172 Oxidative stress has been reported to induce 
haem oxygenase in animal and human tissues; such induction can be regarded as an 
antioxidant defence mechanism. 173 Under stress conditions, haem oxygenase can 
decrease the levels of the haem and haemoproteins such as cytochrome P450 and 
protoporphyrinogen oxidase while increasing the tissue concentrations of bile 
pigments which possess antioxidant properties. 174 It may be valuable to apply cobalt 
treatment in studying the role of haem oxygenase and cytochrome P450 in N-oxide 
reduction. The ability of haem oxygenase to act as a reductase in hypoxic conditions 
that reduces N-oxides is considered and will be investigated in this project. 
1. 4 Aliphatic tertiary amine N-oxides as antiarrhythmic 
prodrugs 
1.4. 1 Lignocaine N-oxide 
Lignocaine has been shown to reduce ventricular arrhythmias associated with 
myocardial infarction and ischaemic myocardial injury. The protective effect of 
lignocaine has been attributed to its membrane stabilising properties. Lignocaine is 
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the drug of choice in the acute treatment of myocardial arrhythmia. The high first-
pass effect and narrow therapeutic index of this agent do, however limit its use. 
Ideally as a prodrug, lignocaine N-oxide, is expected to be pharmacologically inactive 
and relatively stable in vivo until it is reduced back to the parent compound, 
lignocaine, at the site of action (hypoxia selective). Lignocaine N-oxide, like most 
aliphatic amine N-oxides, is more polar and less potent (non-toxic) compared to its 
parent compound, lignocaine.
175 
It would be suitable to use it as a putative hypoxia-
selective antiarrhythmic prodrug to study the feasibility of this approach to drug 
targeting in the hypoxic/ischaemic heart. 
Lignocaine, which is an aliphatic tertiary amine, could be expected to be metabolised 
through N-oxidation with the formation of a tertiary amine N-oxide. However, 
lignocaine N-oxide was identified, only as a minor metabolite of lignoaine, in rat liver 
microsomes.
176 
In rat liver microsomes, lignocaine is N-deethylated to two active 
metabolites, monoethylglycinexylidide (MEGX) and glycine xylidide (GX); and can 
be hydroxylated to 3-or 4-hydroxylignocaine (3-0H-LIG or 4-0H-LIG). 37,38,39,40,44 
The metabolic pathway of lignocaine is shown in Figure 1-8. 
1.4.2 Analysis of tertiary amine N-oxides 
Aliphatic tertiary amine N-oxides are extremely water soluble, thermolabile, and 
unstable at extremes of pH. 72, 177 Despite this lability and the fact that the polarity of 
N-oxides makes their isolation from biological fluids difficult. Analytical techniques 
have been developed for the isolation, identification and quantification of the intact 
aliphatic tertiary amine N-oxides from biological media. The physical-chemical 
properties of the N-oxides influence the choice of assay method and probably account 
for the fact that direct analysis of tertiary amine N-oxides has not been studied in 
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Figure 1-8 Scheme for lignocaine metabolism 
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Gas chromatography (GC) is a rapid and sensitive analytical method. Aliphatic 
tertiary amine N-oxides are highly polar and possibly thennally labile that need to be 
chemically modified before being analysed by GC. Unfortunately, aliphatic tertiary 
amine N-oxides have been shown to decompose during the chemical modification 
using acid anhydrides or acid chlorides to tertiary amines. Therefore, gas 
chromatography (GC), is not considered suitable for use in the aliphatic tertiary amine 
N-oxide metabolism studies. 
High performance liquid chromatography (HPLC) has been successfully used in the 
direct identification and quantification of tertiary amine N-oxides. 178 Two important 
features ofHPLC that facilitate the extraction, recovery and stability of N-oxides and 
metabolites in biological matrices are its operation at ambient environment and the 
capability of polar compound analysis, HPLC analysis of many N-oxides including 
diltiazem N_oxide,179 several antihistamine N-oxides (brompheniramine N-oxide, 
chlorpheniramine N-oxide, pheniramine N-oxide and pyrilamine N-oxide), 180, 181 
" 'N 'd 182 hI 'N·d 1 I3 183 h b did ImIpramme -OXl e, c orpromazme -OXI e' ave een eve ope. 
, I' . d' b l·t . HPLC 35 GC 184 185 d AnalYSIS of IgnocaIne an ItS meta 0 1 es usmg , 'an gas 
chromatography/mass spectrometry (GC/MS) 186 is well documented. The separation 
and identification of lignocaine and lignocaine N-oxide has been reported by Prof. 
Patterson et al. In 1986 using thin-layer chromatography (TLC). However, no reports 
showing the quantification of lignocaine N-oxide by any analytical methods have 
been published. Thus, a priority to study lignocaine N-oxide as an antiarrhythmic 
prodrug was to develop a rapid and sensitive analytical method. 
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1. 5 The aims/objectives 
The aim of this study is to investigate the fate of lignocaine N-oxide in biological 
systems as part of a feasibility study into its use as a bioreductive antiarrhythmic 
pro drug that functions selectively under hypoxic conditions to generate the active 
parent drug, lignocaine. The metabolism and enzymology of lignocaine N-oxide in 
heart and liver tissues will be carried out to assess the capability of the site specific 
biotransformation for this proposed antiarrhythmic prodrug. Preliminary studies in 
vivo will also be conducted to assess the systemic stability of lignocaine N-oxide. 
The objectives of this thesis are: 
1. To develop and validate an HPLC analytical method for the detennination of 
lignocaine N-oxide and its principal metabolites. 
2. To determine aerobic and anaerobic metabolism of lignocaine N-oxide in rat 
liver and heart subcellular fractions and purified enzymes. 
3. To study the mechanism of lignocaine N-oxide bioreduction with particular 
reference to haemoproteins including cytochrome P450, haem oxygenase and 
myoglobin. 
4. To undertake preliminary studies in vivo concerning the metabolic fate of 
lignocaine N-oxide in rat isolated perfused heart. 
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Chapter 2 Experimental 
2.1 Materials 
2.1.1 Materials 
Lignocaine N-oxide, amiodarone N-oxide, diltiazem N-oxide and disopyramide 
N-oxide were synthesised under contract by Dr. D. Rathbone, Aston Molecules, 
Birmingham, U.K.. The compounds were shown to be authentic and pure by NMR, 
mass spectroscopy and elemental analysis. 
Monoethylglycinexylidide (MEGX) was synthesised using the method of Keenaghan 
et aI., 1972 36. The purity and authenticity of this compound was demonstrated by IR 
spectroscopy and HPLC. 
The following chemical and biochemical materials were purchased from Sigma 
Chemical Co. (Poole, Dorset, U.K.): ammonium sulphate, calcium chloride (CaCI2 • 
6H20), cobalt chloride (CoCI2 .6H20), DEAE cellulose, disodium hydrogen 
phosphate, 5,5-dimethyl-I-pyrroline N-oxide (DMPO), dimethylsulphoxide (DMSO), 
disopyramide, ferric chloride (FeCI3), ethylenediaminetetraacetic acid (EDT A), 
ferrous sulphate (FeS04. 7H20), D-glucose, D-glucose 6-phosphate dehydrogenase, 
D-glucose-6-phosphate monosodium salt, haemin, I-heptane sulphonic acid sodium 
salt, hydrogen peroxide, L-ascorbic acid, lignocaine hydrochloride, magnesium 
chloride (MgCI2 • 6H20), methylamine (4.0 M, aqueous solution), nicotinamide 
adenine dinucleotide phosphate (NADP), nicotinamide adenine dinucleotide 
phosphate (NADPH), potassium chloride, potassium dihydrogen phosphate 
(KH2P04), disodium hydrogen phosphate (Na2HP04 ), sodium dithionite (Na2S20 4), 
sodium chloride, sodium hydrogen carbonate (NaHC03), catalase, superoxide 
dismutase (SOD, xanthine oxidase and tris(hydroxymethyl)aminomethane. 
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Acetonitrile and methanol were ofHPLC grade. Triethanolamine, acetic acid and 
hydrochloric acid (10M) were analytical grade. 
Celite (acid-washed) and Sephadex G-15 and G-I00 were from Pharmacia (Herts, 
U.K.). 
Purified rat liver Cytochrome P450 reductase was provided by Professor C. R. Wolf, 
Biomedical Research Centre, Ninewells Hospital Medical School, Dundee. 
Phenotyped human liver microsomes and analysis of data were provided by Dr. Colin 
Henderson, Imperial Cancer Research Foundation, Molecular Pharmacology Unit, 
Biomedical Research Centre, Level 5, Ninewells Hospital & Medical School, 
Dundee. 
Human recombinant haem oxygenase (HO-l) was provided by Professor P. Ortiz 
DeMontellano, Department of Pharmaceutical Science School of Pharmacy, 
University of California at San Francisco, U.S.A .. 
2.1.2 Buffers and reagents 
Tyrode's solution 
Sodium chloride (40 g), D-glucose (10 g), magnesium chloride (1.016 g), sodium 
dihydrogen phosphate (0.25 g), sodium hydrogen carbonate (5 g), potassium chloride 
( 1. 864 g) and calci urn chloride (1 g) were dissolved in 5 litres of distilled water to 
give a final pH of 7.4. 
0.01 M Phosphate buffer (pH 7.4) 
Appropriate volumes of 0.01 M disodium hydrogen phosphate (1.420 g in 1 litre of 
water) and 0.01 M potassium dihydrogen phosphate solutions (1.3609 g in 1 litre of 
water) were mixed to make a 0.01 M phosphate buffer at a final pH of 7.4. 
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0.1 M Tris-HCI buffer (pH 8.5) 
Tris(hydroxymethyl)aminomethane (2.4 g) and sodium chloride (2 g) were dissolved 
in about 100 ml of water, the pH adjusted to 8.5 with 1 M sodium hydroxide or 1.0 M 
hydrochloric acid and the solution diluted with water to 200 ml. 
NADPH generating system 
The NADPH generating system consisted ofNADP (10 f..lmole), glucose-6-phosphate 
(5 f..lmole), glucose-6-phosphate dehydrogenase (1 unit) and 1 f..ll magnesium chloride 
solution (50% w/v) in 100 f..ll of 0.01 M phosphate buffer (pH 7.4). 
2.1.3 Preparation of subcellular fractions from rat liver and 
heart 
Freshly prepared livers and hearts were obtained from adult male rats (Sprague-
Dawley strain) provided by the Pharmacology section, De Montfort University. 
Homogenisation and ultracentrifugation (Beckman L8 ultracentrifuge) were used to 
prepare the subcellular fractions as follows. 
Rat livers or hearts were excised and rinsed with ice-cold 0.01 M phosphate buffer 
(pH 7.4) to remove any blood. After the tissue was blotted dry, it was weighed, cut 
into small pieces and added to 0.01 M phosphate buffer (pH 7.4) of twice the volume 
of the wet organ weight. Suspensions containing finely sliced tissues were 
homogenised with a motor driven Teflon pestle in a Potter- Elvenjehm homogeniser 
by seven to ten repeated passes of the pestle at a speed of 800-1000 r.p.m .. The 
homogenate was then centrifuged at 4°C, with a fixed angle rotor head (8 x 50 rol), 
for 30 min at 10,000 g. The centrifuge tube after this stage contained a supernatant, 
and a pellet that consisted of nuclei, mitochondria, unbroken liver cells and red blood 
cells. The supernatant (S9) was retained and distributed into cellulose nitrate tubes 
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(13.5 ml) and further centrifuged at 140,000 g for 60 min, using a fixed angle (type 
65) rotor head. Supernatant containing soluble cytosolic fraction and a pelIet 
(microsomes from the liver and sarcosomes from heart) were obtained and stored in 
liquid nitrogen before use. The microsomal! sarcosomal suspension was prepared by 
resuspending the pellet in a volume of 0.01 M phosphate buffer (pH 7.4) equal to the 
originalliver/heart wet weight using a hand held Potter-Elvenjehm homogeniser. The 
protein content of each subcellular fraction was determined using the Bio-Rad protein 
assay (see Appendix I). 
2.1.4 Purification of bovine myoglobin 
Myoglobin of high purity was obtained as deoxymyoglobin from fresh bovine heart 
muscle and was shown to be free of metmyoglobin as an intermediate. All 
procedures were performed at about 4°C as follows l88, 189, 190, 191. 
Fresh bovine heart muscle (1.7 kg), free of connective tissue was homogenised with 
approximately 1 litre of 5 mM Tris-HCl buffer, pH 8.5 and the homogenate was 
centrifuged at 4000 g for 10 min. Appropriate amounts of 1 M Tris-HCI buffer or 
1 M NaOH solution were added to the supernatant to adjust the buffer concentration 
to 20 mM, pH 8.5. Solid ammonium sulphate (ultrapure) was then added to achieve 
70% saturation. After one hour, the precipitate, which was collected by 
centrifugation at 20,000 g for 15 min, was discarded. Addition of more ammonium 
sulphate to saturation gave a precipitate that was collected on Celite (acid-washed). 
The aqueous extract obtained by treatment of the Celite crude deoxymyoglobin 
mixture with 5 mM Tris-HCI buffer (pH 8.5), was applied to a column, equilibrated 
with 5 mM Tris-HCI buffer (pH 8.5), consisting of a top layer (6.5 x 5 cm) of 
Sephadex G-15 and a bottom layer (6.5 x 65 cm) ofSephadex G-IOO. The 
deoxymyoglobin was eluted from the column with the same buffer and dialysed 
overnight against the buffer. The deoxymyoglobin solution was then placed on a 
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column (6 x 10 cm) ofDEAE cellulose equilibrated with 5 mM Tris-HCI buffer (pH 
8.5), and washed with 1 column volume of the same buffer. Most of the 
deoxymyoglobin was seen to remain on the lower portion of the column and was 
removed by elution with 30 mM Tris-HCI buffer (pH 8.5). FollOwing dialysis for 5 
hours against 5 mM Tris-HCI buffer (pH 8.5) the deoxymyoglobin solution was 
placed on a column (6 x 1.5 cm) ofDEAE cellulose (DE52) equilibrated in 5 mM 
Tris-HCI buffer (pH 8.5). Metmyoglobin was collected from the DE52 column in 
5mM Tris-HCI buffer, pH 8.0. Deoxymyoglobin was further eluted from the column 
with 0.1 M Tris-HCI buffer, pH 8.5. Any metmyoglobin remaining was removed by 
repeating this procedure. Deoxymyoglobin was purified freshly before use. 




in 10 mM Tris-HCI buffer (pH 8.5).192 Ferryl myoglobin was freshly prepared and 
quantified spectrophotometrically before use. All myoglobins were stored at -5°C 
and protected from light. The concentration of myoglobin was measured by the Bio-
Rad method as described in Appendix I. 
2.2 Analytical methods 
A series of reversed-phased HPLC columns with various packing materials (C6, C8, 
and C18) and different column length (15 cm and 25 cm) were tested. The 
constituents (e.g. phosphoric acid, acetic acid, citric acid, phosphate buffers, acetate 
buffers and triethanolamine) and pH value of the mobile phase were investigated to 
achieve good separation of lignocaine N-oxide and its metabolites. Different 
proportions of methanol and acetonitrile were added into aqueous solutions to acquire 
a satisfactory elution with the mobile phase. The final HPLC conditions are as 
described in section 2.2.1. 
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Protein samples containing lignocaine N-oxide and its metabolites must not be 
directly injected onto an HPLC column in order to maximise the column life. Various 
deproteination and extraction schemes, e.g. methanol, acetonitrile, chloroform and 
dichloromethane under acidic or basic conditions, were tested in order to achieve 
good recovery and prevent compound decomposition. The sample handling 
procedures used in this study is described in section 2.2.2. 
2.2.1 High performance liquid chromatography (HPLC) of 
lignocaine N-oxide and its major metabolites 
The HPLC system consisted of a Philips PU41 00 liquid chromatograph, a model 
PU4110 UV NIS variable-wavelength detector, a model PU4700 autoinjector. Data 
and chromatograms were recorded. Peak heights and areas were calculated using 
Jones JCL 6000 data processing software. 
The stationary phase consisted of a Jones 5 /-lm octyl stainless steel cartridge column 
(4.6 x 150 mm I.D.) and a 5 /-lm octyl guard column (4.6 x 20 mm I.D.). 
Chromatography was performed at room temperature using a mobile phase consisting 
of methanol-acetonitrile-water containing 5 mM I-heptanesulphonic acid sodium salt, 
triethanolamine (4% v/v) and acetic acid (4% v/v), pH 4.8 (16 : 16: 68) at a flow rate 
of 1.5 mllmin. The UV detector was set at 250 nm. 
2.2.2 Sample preparation 
In the metabolism experiments, the samples contained 100 /-ll of freshly prepared 
NADPH generating system; 50 J.lI of drug/metabolite solution, 50 J.lI of biological 
sample (protein content indicated for each experiment), and 50 /-ll of 0.01 M 
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phosphate buffer (pH 7.4) to make a final volume of250 J.d. Any constituent omitted 
in this sample preparation formula was replaced by 0.01 M phosphate buffer (pH 7.4) 
to maintain a final incubation volume of 250 J..tl. Protein concentrations (protein 
assay as shown in the Appendix I) were measured in biological samples (e.g. rat heart 
and liver subcellular fractions). 
In the incubation studies, all samples were deproteinated and extracted by the 
following method. The 250 !J,l sample was acidified with 50 !J,l of 1.0 M hydrochloric 
acid, and 200 !J,l of acetonitrile containing disopyramide (12.5 !J,g/ml), as internal 
standard, added. The sample was then vortex mixed and chilled thoroughly in ice. 
Following centrifugation at 1,000 g for 10 min (Jouan, BEMA-C), the supernatant 
was analysed by HPLC. Peak height ratios (sample peak height/internal standard 
peak height) or peak area ratios were used to calculate the amount of drug and its 
metabolites contained in the biological samples. The concentrations of drug and 
metabolite were quantified from calibration graphs prepared using biological 
suspensions with known amounts of drug or metabolite added. 
In the haem and NADPH supplemented cytochrome P450 and haem oxygenase 
studies, blanks and samples were incubated anaerobically in a glove box by purging 
the incubation mixtures with nitrogen and maintaining the incubation mixtures in an 
atmosphere of nitrogen (see section 2.3.1). 
2.2.3 Validation of analytical method 
Five calibration standards with known concentrations of lignocaine N-oxide (40-
200J.!M) and its presumed metabolites, lignocaine (42-210 J.!M) and MEGX (49-245 
!J,M), were prepared in rat liver microsomes (protein content, 6.0 mg/ml). These 
standards were processed by the HPLC sample preparation procedure (see Section 
2.2.2) and suitable aliquots injected into the HPLC. Calibration data from these 
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standard curves were obtained daily, in triplicate, for at least 3 days. Standards were 
also routinely injected during sample HPLC analysis to evaluate the reproducibility of 
this system. 
Samples of rat liver micro somes (protein content, 6.0 mg/ml), heart S9 fractions 
(protein content, 10.7 mg/ml), sarcosomes (protein content, 3.7 mg/ml) and cytosol 
(protein content, 7.5 mg/ml) containing known concentrations of lignocaine N-oxide 
(up to 200 f.lM), lignocaine (up to 210 JlM) and MEGX (up to 245 J.tM) were prepared 
following the HPLC sample preparation method and analysed by HPLC (see Section 
2.2.2). Recoveries were obtained by comparing the results for each compound in the 
biological samples with those for standard drug solutions prepared in 0.01 M 
phosphate buffer (pH 7.4). 
2.3 The metabolism of lignocaine N-oxide in rat tissues 
2.3.1 Control of oxygen availability 
All experiments were performed inside an airtight glove box (690 x 430 x 400 mm). 
The glove box was evacuated via flow meters and the amounts of compressed air and 
nitrogen were introduced to produce oxygen concentrations from 0 to 20% mgIL (31-
625 JlmolelL of oxygen). Oxygen concentrations were monitored using a Clarke-type 
oxygen electrode (Strathkelvin Instruments, Glasgow, U.K., model 781) at the 
incubation temperature of 37°C, throughout each incubation period. During the 
incubation studies all solutions used were kept under the desired oxygen 
concentration before and throughout the experiments. Biological samples were 
incubated and analysed by HPLC (as described in section 2.2). Each experiment was 
performed at least in triplicate. 
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2.3.2 Control studies for lignocaine N-oxide metabolism 
A series of experiments were carried out to investigate the requirement for each 
incubation component in lignocaine N-oxide metabolism. The constituents of the 
NADPH generating system (NADP, glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, MgCI2), the NADPH generating system (NADPH) and rat liver 
microsomes were each omitted from the total incubation mixture. Anaerobic 
incubation of lignocaine N-oxidation and rat heart homogenate was carried out with 
and without the addition ofNADPH generating system. 
The fate of lignocaine (336 J.1M) with rat liver microsomal suspensions (protein 
content, 6 mg/ml), and lignocaine N-oxide (200 J..1M) with rat heart S9 suspension 
(protein content, 2.7 mg/ml) was studied under anaerobic conditions for 90 minutes. 
Samples were handled and analysed following the standard analytical scheme as 
described in section 2.2. 
2.3.3 Metabolism of lignocaine N-oxide under anaerobic 
conditions 
Anaerobic conditions were produced by deaerating the incubation mixtures with 
nitrogen. Incubation mixtures (250 J..1l) were NADPH supplemented and prepared as 
described in section 2.2.1. Samples were incubated anaerobically using a glove box 
as described in section 2.2.3.1. Lignocaine N-oxide (200 J..1M) was incubated in rat 
liver microsomal suspensions (protein content, 6 mg/ml) for 50 min. Lignocaine 
N-oxide (200 ~) was incubated for 60 minutes with rat heart subcellular fractions. 
The fractions used were heart S9 suspension (protein content, 2.7 mg/ml), sarcosomes 
(protein content, 0.8 mg/ml) and cytosol (protein content, 1.6 mg/ml). All samples 




2.3.4 Effect of oxygen tension on lignocaine N-oxide reduction 
Incubations under various oxygen concentrations from 0 to 20% were performed in a 
closed system as described in section 2.3.1. Lignocaine N-oxide (200 J..lM) in 
NADPH supplemented rat liver microsomal suspensions (protein content, 3.6 mg/ml) 
were incubated under different oxygen tensions for 15 min. Rat heart homogenate 
(protein content, 2.15 mg/ml) and heart subcellular fraction (S9, protein content, 2.5 
mg/ml) were incubated under several different oxygen tensions for 10 min. All 
samples were handled and analysed as described in section 2.2. 
2.3.5 Enzyme kinetics of lignocaine N-oxide reduction 
The enzyme kinetic constants for the reduction of lignocaine N-oxide were 
determined in rat liver microsomes and heart subcellular fractions. The optimal 
conditions for N-oxide reduction with respect to substrate and protein concentration 
under anaerobic conditions was investigated. 
2.3.5.1 Enzyme kinetics of lignocaine N-oxide reduction in rat liver 
microsomes 
Incubation mixtures of rat liver micro somes (protein content, 6 mg/ml) with different 
concentrations of lignocaine N-oxide (40-400 J..1.M) were incubated for 5 min. 
Different volumes of a standard rat liver microsomal suspension (protein content, 6 
mg/ml ) were used to vary the protein (enzyme) concentration (60-1270 J..lg/ml) in 250 
J..lI incubation mixtures containing lignocaine N-oxide (200 J..1.M). Five-minute 
incubations were carried out under anaerobic conditions. 
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2.3.5.2 Enzyme kinetics of lignocaine N-oxide reduction in rat heart 
subcellular fraction 
Different concentrations (30-400 JlM) of lignocaine N-oxide in rat heart S9 
suspension (protein content, 2.36 mg/ml) were incubated for 10 min. Different 
volumes of a standard rat heart S9 suspension were used to vary the protein (enzyme) 
concentration (0.47-4.72 mg/ml) in 250 Jll incubation mixtures with a fixed 
lignocaine N-oxide concentration of 200 1lM. Incubations were carried out under 
anaerobic conditions for 10 min. All incubation mixtures were prepared and handled 
according to the standard procedure as described in section 2.2 and analysed by 
HPLC. 
2.3.6 In vivo metabolism of lignocaine N-oxide in the rat 
An intraperitoneal injection of lignocaine N-oxide (10 mg/kg) was given to a male rat 
(weight, 307 g). Urine samples were collected for 24 hours from this rat and a non-
dosed control rat (weight, 320 g). Pooled rat urine samples were filtered through 2 
Jlm sample filters, and analysed by HPLC following sample preparation as described 
in section 2.2. Lignocaine N-oxide was added to a sample of blank urine and the 
solution was left for 24 hours at room temperature. 
2.3.7 Metabolism of lignocaine N-oxide in isolated perfused rat 
heart 
Metabolism of lignocaine N-oxide was studied using perfused rat hearts. Whole 
hearts from male rats (Sprague-Dawley, 6-12 months) were perfused via a 
Langendorff preparation. The perfusion medium was Tyrode's solution, gassed with 
02: CO2 (95:5%) at 37°C and the perfusion rate was 16 ml/min. Freshly prepared rat 
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hearts (weighing 2.5-3.0 g), were placed in the apparatus and stabilised by perfusion 
for 15 min. Further perfusion of either Tyrode's solution, lignocaine N-oxide (500 
J..lM) or lignocaine (500 J..lM) in Tyrode's solution, were then continued for 10 min. 
Perfusion was then stopped for 10 min to achieve anoxic conditions. The perfusion 
fluids collected from the hearts were collected for analysis. The perfused rat heart 
was rapidly frozen in liquid nitrogen to prevent any further metabolism. The whole 
heart was weighed and homogenised at 0-5 °C (in ice) and the homogenates were 
then diluted with 0.01 M phosphate buffer (pH 7.4) to make a suspension containing 
0.2 g heart tissue Iml. All samples were maintained at 0 °C and analysed immediately 
byHPLC. 
2.3.8 Lignocaine N-oxide metabolism in cytochrome P450 
phenotyped human liver microsomes 
Samples containing 50 J..lI phenotyped human liver micro somes (approximate 0.3 
mg/lnl), NADPH (1 mM) and lignocaine N-oxide (100 J.1M) in phosphate buffer (pH 
7.4,0.1 mM) with a final volume of250 J..lI were incubated anaerobically at 37°C for 
20 min. All samples were processed and analysed according to the standard 
procedure as described in section 2.2 and analysed by HPLC. 
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2.4 Mechanistic studies on N-oxide bioreduction 
2.4.1 Effect of enzyme inhibitors on lignocaine N-oxide 
reduction 
All incubation mixtures contained NADPH supplemented tissue (rat liver micro somes 
or heart S9 fractions), lignocaine N-oxide (200 /-!M) and were maintained under 
anaerobic condition as described in section 2.2. In selected incubations either carbon 
monoxide was added for 60 seconds, or KCN (0.1 roM) added or lignocaine (200 !J.M) 
added or functional tissue replaced with denatured (boiled) tissue. Following 
incubation for 20 min all samples were processed and analysed by HPLC as described 
in section 2.2. 
2.4.2 Visible light difference-spectrum studies of lignocaine 
N-oxide binding to rat liver microsomes 
Visible light difference spectroscopy was used to study the binding of lignocaine and 
lignocaine N-oxide to microsomal cytochrome P450 under oxidised or reduced 
conditions. Spectroscopic examination of microsomal suspensions (0.2 mg/ml) was 
carried out under air (oxidised microsomes) and under reduced conditions. Reduced 
microsomal suspensions were prepared by adding 500 mg of sodium dithionite 
(Na2S204) to 5 ml of microsomal suspensions. Volumes (50 Jll) of lignocaine or 
lignocaine N-oxide stock solutions (4 roM) in 0.01 M phosphate buffer (pH 7.4) were 
added to 2.0 ml of either oxidised or reduced microsomal suspensions. In all 
microsomal suspensions, the final drug concentrations were between 0 and 16 !J.M. 
The spectra were recorded between 340-500 run using a double beam 
spectrophotometer, Perkin Elmer 550S. The reference solutions, consisting of 
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appropriately treated microsomal suspensions, were as described above, without the 
addition of drug solutions. All experiments were perfonned at room temperature. 
2.4.3 Effect of cobalt treatment of rats on in vitro lignocaine 
N-oxide reduction 
Three male rats (Sprague-Dawley, weighing about 500 g) were each given two 
subcutaneous injections of cobalt chloride (60 mglkg) at 24 hour intervals. The rats 
were then starved for 24 hours and killed by decapitation. The cytochrome P450 and 
bs levels in the liver microsomal suspensions of the three dosed rats and a control rat 
were measured as described in the Appendix II. Lignocaine N-oxide (200 /-lM) was 
incubated in NADPH supplemented dosed and control rat liver microsomal 
suspensions (6.8 mg/ml) for 40 min under anaerobic conditions as described in 
section 2.2 and analysed by HPLC. 
2.4.4 Involvement of haem, haem oxygenase, cytochrome P450 
reductase and xanthine oxidase in lignocaine N-oxide 
reduction 
2.4.4.1 Cytochrome P450 reductase and haem oxygenase 
Samples containing lignocaine N-oxide (1 00 ~), purified rat liver cytochrome P450 
reductase (3 J..lI, specific activity 3 nmole NADPH reduced per min), haem oxygenase 
(2 I.d, specific activity 0.7 nmole biliverdin fonned per min), haemin (40 J.1M) and 
NADPH (200 J.!M) in 0.01 M phosphate buffer (pH 7.4) in a final volume of 100 /-ll 
were incubated anaerobically for 60 min. Studies were also carried out omitting 
NADPH, haem, haem oxygenase or cytochrome P450 reductase. 
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2.4.4.2 Xanthine oxidase 
Incubation mixtures (final volume 250 J,.ll) containing lignocaine N-oxide (100 J,.lM), 
both milk xanthine oxidase (1 unit) and NADPH (200 J,.tM) in 0.01 M phosphate 
buffer (pH 7.4) were incubated anaerobically with and without the addition of haemin 
(40 mM) for 60 min. 
In all the above procedures, the incubates were analysed by HPLC following 
deproteination and extraction as described in section 2.2. Suitable blank incubates 
were analysed by HPLC in the same manner and at the appropriate time. 
2.4.5 Reduction of lignocaine N-oxide by myoglobin, 
haemoglobin and viable myocytes 
Deoxymyoglobin and metmyoglobin prepared as described in section 2.1 in 
1.0 M Tris-HCI buffer (pH 7.4) were diluted with 0.01 M phosphate buffer (pH 7.4) to 
obtain protein contents equivalent to 1 mg/ml. Deoxyhaemoglobin and 
methaemoglobin (protein content 1mg/ml) were diluted with 0.01 M phosphate buffer 
(pH 7.4) to make protein contents equivalent to 1 mg/ml. Myocytes were prepared in 
0.01 M phosphate buffer (pH 7.4) with 106 cells per sample. Sample solutions were 
incubated under anaerobic conditions with lignocaine N-oxide (100 11M) for 2 hours. 
The total volume of the incubation mixture was 250 Ill. All solution used were 
carefully degassed under nitrogen to ensure fully anaerobic conditions. Samples were 





Influence of oxygen tension on lignocaine N-oxide 
reduction by myoglobin 
Under carefully controlled conditions as described in section 2.3, samples containing 
deoxymyoglobin (protein content, 1 mglml) and lignocaine N-oxide (100 JIM) in a 
final volume of 250 III were incubated under various oxygen concentrations for 2 hr. 
The oxygen content in this system was varied from between 0 and 20%. Samples 
were processed and analysed by HPLC as described in section 2.2. 
2.4.7 Reduction of lignocaine N-oxide by inorganic iron and 
haem 
Lignocaine N-oxide (100 IlM) was incubated anaerobically for 60 min with freshly 
prepared ferric chloride (Fe +3, 1 mM), ferrous sulphate (Fe +2, 1 mM) and haemin 
(1 mM) with or without the addition of EDT A (metal chelating agent, ImM) in 0.01 
M phosphate buffer (pH 7.4). Anaerobic incubations (60min) of lignocaine N-oxide 
and haemin with or without the addition of ascorbic acid (1 mM) and NADPH 
(prepared from NADPH generating system as described in section 2.l.2) were carried 
out to investigate N-oxide reduction by reduced and oxidised haem. Incubations with 
only NADPH and ascorbic acid were performed as control studies. Samples were 





Interaction of lignocaine N-oxide with iron and 
myoglobin as determined by electron spin resonance 
spectrometry 
In the mechanism studies of N-oxide reductio~ electron spin resonance (ESR) 
spectrometry was used to detect lignocaine N-oxide reduction. A Varian E3 X-band 
electron spin resonance (ESR) spectrometer was used and operated at room 
temperature. The operating conditions were: microwave power 10 mW; microwave 
frequency 9.44 G; magnetic field 3395 G; modulation amplitude 1.25 G; receiver gain 
3.2 x 105; scan range 50 G; time constant 0.3 second and scan time 4 min. The quartz 
flat cells and all components used were checked individually to ensure that no 
interfering ESR signals occurred. A spin trapping agent, 5,5-dimethyl-l-pyrroline 
N-oxide (DMPO, 1 mM) was added to samples. 
Electron spin resonance spectra of ferrous iron (FeS04, 1 mM), deoxymyoglobin (50 
J.lg), metmyoglobin (50 J.lg) and ferryl myoglobin (50 J.lg) were recorded in the 
presence of lignocaine (1 mM), lignocaine N-oxide (1 mM), methylamine (250 Ill) 
hydrogen peroxide (H20 2, 100 mM), EDTA (ImM), superoxide dismutase (1 unit), 
catalase (1 unit) or DMSO (250 J.lI). A series of experiments were carried out using 
ESR spectroscopy to detect possible free radical formation from the interactions of 
lignocaine N-oxide and myoglobin (Table 2-1). All samples were prepared in 0.01 M 
phosphate buffer (pH 7.4) containing a spin trapping agent, DMPO (100 mM) and a 
final volume of 500 J.ll. All experiments were performed under anaerobic conditions 
unless specifically indicated. 
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Table 2-1 Experimental conditions, components added and their concentrations 
in the electron spin resonance spectroscopy studies of lignocaine N-oxide 
Component added Experimental condition 
Anaerobic Aerobic 
DMPO(ImM) ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 
FeS04 (1mM) ~ ~ -J 
EDTA(1mM) -J ~ -J 
Hydrogen peroxide (1 OOmM) ~ ~ ~ -J 
Deoxymyoglobin (50mg) ~ ~ ~ ~ ~ ~ ~ 
Metmyoglobin (50mg) ~ ~ 
Ferryl myoglobin (50mg) ~ ~ ~ ~ ~ 
Lignocaine (1 mM) -J ~ ~ 
Lignocaine N-oxide (ImM) ~ ~ ~ ~ -J 
DMSO (250mg) ~ -J 
Methylamine (250ml) ~ 
i 
SOD (I unit) +catalase (1 unit) ~ \j 
Experimental details were as described in section 2.4.8. 
~ Components added. 
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Spectral binding studies of lignocaine N-oxide with 
myoglobin 
UY/visible light difference spectroscopy was used to study lignocaine N-oxide 
reduction in the presence of myoglobin. Myoglobin was prepared as described in 
section 2.1. Myoglobin solutions were adjusted to pH 7.4 with 0.1 M hydrochloric 
acid and fully degassed with nitrogen before use. Experiments were subsequently 
carried out under anaerobic conditions. The reference solutions consisted of 
appropriate myoglobin solutions without the addition of lignocaine N-oxide. 
The binding of lignocaine N-oxide (12.5 roM) and lignocaine (12.5 roM) with 
deoxymyoglobin, metmyoglobin and ferryl myoglobin (all myoglobin protein 
concentrations were 0.5 mg/mI) were examined. The spectral changes that occurred 
between 200 and 600 nm were recorded using a double beam spectrophotometer 
(Perkin Elmer, 550S). Lignocaine N-oxide was incubated with myoglobin at 37°C for 
60 min under anaerobic conditions. 
Solutions containing deoxymyoglobin (0.45 mg/mI) were incubated anaerobically 
with lignocaine N-oxide (1 mM), amiodarone N-oxide (1 mM), diltiazem N-oxide 
(1 mM) or disopyramide N-oxide (1 mM) for 2.5 hr at 37°C. Difference UY/visible 
spectra were recorded on a double beam spectrophotometer (Perkin Elmer, 550S) at 
intervals during incubation. 
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Chapter 3 Results 
3.1 HPLC analysis of lignocaine N-oxide and metabolites 
The chromatographic method developed allowed the analysis of lignocaine N-oxide, 
lignocaine and monoethylglycinexylidide (MEGX), the major metabolite of 
lignocaine in rat liver microsomes36. Analysis of suitable control samples showed 
that the biological material per se did not produce interfering peaks. 
Typical chromatograms obtained from the HPLC analysis of rat liver microsomal 
suspensions spiked with authentic lignocaine N-oxide, lignocaine and MEGX are 
shown in Figure 3-1. HPLC chromatograms of rat heart S9 fraction, sarcosome and 
cytosol containing lignocaine N-oxide, lignocaine and MEGX are shown in Figure 
3-2. The retention times were MEGX (6.0 min), lignocaine N-oxide (7.5 min), 
lignocaine (8.5 min) and disopyramide (12.8 min). 
Table 3-1 and Figure 3-3 show the calibration data for analysis of lignocaine, 
lignocaine N-oxide and MEGX in rat liver microsomal suspensions. The square 
correlation coefficient (r2) for lignocaine (42-210 J,.tM), lignocaine N-oxide (40-200 
J,.tM) and MEGX (49-246 J..tM) in the presence of rat liver microsomes are all greater 
than 0.998. The method was shown to be accurate and precise through the low 
variation of inter- and intra- experimental results. The day-to-day reproducibility of 
the assay is shown in Table 3-2. The coefficient of variation (C.V., %) values for 
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Figure 3-1 HPLC chromatograms of (A) rat liver microsomes containing: (1) 
monoethylglycinexylidide (2) lignocaine N-oxide (3) lignocaine and (4) disopyramide 
(internal standard); (B) rat liver microsomes containing internal standard. 
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Figure 3-2 HPLC chromatograms of (A) blank rat heart subcellular fractions (S9) 
and (B) rat heart S9 fractions (C) sacrosomes (D) cytosolic suspension containing: 
(l)lignocaine N-oxide (2) lignocaine and (3) disopyramide (internal standard). 
HPLC conditions were as described in section 2.2. I. 
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Table 3-1 HPLC calibration data for lignocaine N-oxide, lignocaine and 
monoethylglycinexylidide in the presence of rat liver microsomes 


































HPLC analysis was performed as described in section 2.2.3. 








Peak height ratio= analyte peak height/internal standard peak height 
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Figure 3-3 Calibration graph for lignocaine N-oxide, lignocaine and 
monoethylglycinexylidide in rat liver microsomal suspensions. 
Results are the mean ± s.d. of three determinations, see section 2.2.3 for 
experimental details. 
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Table 3-2 Inter day variation of analysis of lignocaine N-oxide,lignocaine and 
monoethylglycinexylidide in the presence of rat liver microsomes 
Compound Concentration (J,tM) 
added found 
lignocaine N-oxide 40 39.92 ± 0.19 
80 79.77 ± 0.24 
120 121.31 ± 1.43 
160 161.54 ± 3.52 
200 200.02 ± 7.53 
lignocaine 42 40.92 ± 0.32 
84 83.76 ± 2.42 
126 125.17 ± 1.45 
168 169.42 ± 0.67 
210 211.02 ± 2.58 
MEGX 49 50.00 ± 2.25 
98 97.98 ± 1.11 
147 145.93 ± 5.25 
196 197.71 ± 8.05 
245 248.10 ± 9.15 
HPLC analysis was performed as described in section 2.2.3. 
All results are the mean ± standard deviation of three replicates. 
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It has been noticed that in this study, a quantification error occurred when extra-
plotting lignocaine N-oxide below the concentration of 50~. The amount of 
lignocaine N-oxide was found to be lower than the actual amount found. A different 
standard curve at the range between 0 and 50 IlM should be used in the quantification 
of lignocaine N-oxide, lignocaine or MEGX to provide precise quantification. In this 
study, no other metabolite except lignocaine has been found. The formation of 
lignocaine is therefore considered to be quantitatively equivalent to the metabolism of 
lignocaine N-oxide. 
The recoveries of lignocaine N-oxide and lignocaine in rat liver microsomal 
suspensions, rat heart subcellular fractions (S9, sarcosome and cytosol) were all 
greater than 92%; the recovery of MEG X was greater than 82% (as shown in Table 
3-3). The lower recoveries of lignocaine and MEGX than lignocaine N-oxide may be 
due to the extraction system used being more suitable for extracting polar compounds 
such as lignocaine N-oxide rather than the more lipophilic protein bound drugs and 
metabolites. 
3.2 Metabolism of lignocaine N-oxide in rat liver and 
heart 
Lignocaine N-oxide was converted to lignocaine in anaerobic rat liver microsomes 
supplemented with NADPH (see Figure 3-4). When lignocaine N-oxide was 
incubated under anaerobic conditions, no reduction occurred in the absence ofNADP, 
glucose-6-phosphate, glucose-6-phosphate dehydrogenase, MgCh , the NADPH 
generating system and microsomes, respectively. Additionally, lignocaine N-oxide 
did not react with any single one of these components upon anaerobic incubation. In 
the rat heart homogenate, no N-oxide reduction occurred in the anaerobic incubation 
without the supplement ofNADPH (from the NADPH generating system). 
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Table 3-3 Intra batch recoveries of lignocaine N-oxide, lignocaine and 
monoethylglycinexylidide in the presence of rat tissue fractions. 
Cell fraction Protein content (mg/ml) Recovery (%) 
lignocaine lignocaine I\1EGX 
N-oxide 
rat liver 
micro somes 6.0 97.09±0.46 97.07±0.25 85.42±I.36 
rat heart 59 
fraction 10.7 96.21±0.21 96.21±0.21 82.64±0.86 
rat heart 
sarcosomes 3.7 94.50±O.36 92. 13±O.31 84.90±O.75 
rat heart 
cytosol 7.5 97.33±0.68 93.07±063 87.42±0.51 
Sample preparation and HPLC analysis were as described in section 2.2. 
Tissue fractions were prepared as described in section 2.1.3. 
All results are the mean ± standard deviation of three replicates. 
MEGX= monoethylglycinexylidide 
Recovery (%) = peak height ratio of analyte in cell fraction 
peak height ratio of analyte in buffer 
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Figure -3-4 Reduction of lignocaine N-oxide by NADPH supplemented rat liver 
mlcrosomes under anaerobic condition. Experimental details as described in section 2.3. 
Results are the mean ± S.d. of three determinations. 
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Lignocaine remained unchanged under anaerobic incubation with rat liver 
microsomes and rat heart homogenate for at least 90 min (Figure 3 5) Thi -. s suggests 
that when lignocaine N-oxide was incubated in this system, any lignocaine formed by 
N-oxide reduction would not be oxidised back to lignocaine N-oxide or be 
convertedlhydrolysed into any other metabolite under the conditions employed. 
3.2.1 Metabolism of lignocaine N-oxide in rat liver and heart 
tissue 
Lignocaine N-oxide and lignocaine were the only substances detected when 
lignocaine N-oxide was incubated, under anaerobic conditions, with either rat liver 
microsomes, rat heart S9 fractions or rat heart cytosol. This together with quantitative 
recovery indicates that no other metabolites were found under the conditions used. 
Lignocaine N-oxide metabolism was complete within 60 min in rat liver microsomes, 
rat heart S9 fractions and cytosolic fractions (Figure 3-4, 3-6 and Figure 3-7). 
Incubation of lignocaine N-oxide with sarcosomes did not result in any detectable 
formation of lignocaine in incubations up to 60 min (Figure 3-8). 
When lignocaine N-oxide was incubated with rat liver microsomal suspension under 
diminished oxygen tension, an decrease in reduction to lignocaine was observed 
proportional to the oxygen content (see Figure 3-9). The formation of lignocaine was 
in proportion to the loss of lignocaine N-oxide. Lignocaine N-oxide reduction was 
suppressed when the oxygen concentration was increased but was not fully inhibited 
under aerobic conditions. Specifically under anaerobic conditions, more than 60% of 
the N-oxide was reduced to lignocaine whilst under aerobic condition less than 16% 
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Figure 3-5 Anaerobic incubation of lignocaine with rat liver microsomes and rat heart 
S9 fractions. Experimental details were as described in section 2.3.2. 
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Figure 3-6 Reduction of lignocaine N-oxide by NADPH supplemented rat heart S9 
fractions under anaerobic conditions. Experimental details were as described in section 
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Figure 3-7 Reduction of lignocaine N-oxide by NADPH supplemented rat heart 
cytosol under anaerobic condition. Experimental details were as described in section 2.3. 
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Figure 3-8 The anaerobic incubation of lignocaine N-oxide in rat heart sarcosomes . 
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Figure 3-9 Effect of oxygen tension on lignocaine N-oxide reduction in NADPH 
supplemented rat liver microsomal suspensions. Experimental details were as described 
in section 2.3. Results are the mean ± s.d. of three determinations. 1 mgIL oxygen = 31.3 
mmole IL oxygen. 
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As shown in Figure 3-10 and Figure 3-11, lignocaine N-oxide reduction was also 
inhibited by oxygen in both rat heart homogenate and S9 fractions. Lignocaine 
production under anaerobic conditions in homogenate and S9 was greater than 75% 
whilst less than 230/0 was converted into lignocaine under aerobic conditions. 
3.2.2 Enzyme kinetics of lignocaine N-oxide metabolism 
The enzyme concentration was controlled by adjusting the protein content in the rat 
liver microsome incubation mixtures. As the enzyme content increased, there was an 
increase in the amount of lignocaine N-oxide metabolised and concomitant formation 
of lignocaine (Figure 3-12). The effect of substrate concentrations on lignocaine 
N-oxide reduction in rat liver microsomes is shown in Figure 3-13. From this data, 
enzyme kinetic constants (Km and Vmax) for lignocaine N-oxide reduction were 
determined using the Lineweaver-Burke linear transformation. These plots are shown 
in Figure 3-14 and the values for Km and Vmax were determined to be 250.0 JJM and 
0.992 nmole/minlmg protein, respectively. 
The effect of enzyme concentration on lignocaine N-oxide metabolism in heart S9, 
cytosol and sarcosomes is shown in Figure 3-15. Lignocaine N-oxide reduction 
increased as protein content increased. The effect of substrate concentration on 
lignocaine N-oxide reduction in S9 fraction is shown in Figure 3-16. The enzyme 
kinetic constants (Km and Vmax) for lignocaine N-oxide reduction were calculated 
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Figure 3-10 Effect of oxygen tension on lignocaine N-oxide reduction in 
NADPH supplemented rat heart homogenate. Experimental details were 
as described in section 2.3. Results are the mean ± s.d. of three determinations. 
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Figure 3-11 Effect of oxygen tension on lignocaine N-oxide reduction in 
NADPH supplemented rat heart S9 fractions. Experimental details were as 
described in section 2.3. Results are the mean ± s.d. of three detenninations. 
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Figure 3-12 Effect of NADPH supplemented rat liver microsomal protein 
concentration on lignocaine N-oxide reduction under anaerobic conditions. Experimental 
details were as described in section 2.3. 
Results are the mean ± s.d. of three determinations. 
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Figure 3-13 Effect of lignocaine N-oxide concentration on its reduction in NADPH 
supplemented rat liver microsomal suspensions under anaerobic condition. Experimental 
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Figure 3-14 Lineweaver-Burk plot for lignocaine N-oxide reduction in NADPH 
supplemented rat liver microsomes. Experimental details as described in section 2.3. 
linear regression equation: Y = 1.0082 + 250.1 X 
Correlation coefficient (r) = 0.9920 
Km= 250.0 ~lM 
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Figure 3-15 Effect ofNADPH supplemented protein concentration of rat heart S9 
fraction on lignocaine reduction under anaerobic conditions. Experimental details were 
as described in section 2.3. Results are the mean ± s.d. of three detenninations. 
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Figure 3-16 Effect of lignocaine N-oxide concentration on its reduction in NADPH 
supplemented rat heart S9 fraction under anaerobic conditions. Experimental details were 
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Figure 3-17 Lineweaver-Burk plot for lignocaine N-oxide reduction in NADPH 
supplemented rat heart S9 fractions. Experimental details as described in section 2.3. 
Linear regression equation: Y = 0.901 + 243.087 X 
Correlation coefficient (r) = 0.990 
KIn = 269.8 ~tM 
Vmax = 1.11 nmolc/minule/nlg protein 
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3.2.3 Lignocaine N-oxide metabolism in isolated perfused rat 
heart 
Lignocaine N-oxide metabolism was investigated in a functional isolated heart 
preparation (Langendorff preparation). Carefully controlled conditions including 
temperature, oxygen and sodium-calcium balance perfusion fluid were applied to 
isolated rat hearts to achieve a steady (normal) cardiac rhythm. Anoxic/arrhythmic 
conditions was achieved by stopping the perfusion fluid. 
Analysis of the homogenates of the perfused and non-perfused rat hearts showed that 
under anoxic condition, 460/0 of lignocaine N-oxide associated with the myocardium 
was metabolised to lignocaine; whilst no metabolism was found in the drug perfused 
rat hearts under oxygen perfusion (Table 3-4). Lignocaine was not found in the 
perfusion fluids collected from either normal (perfused) or anoxic (non-perfused) 
hearts. No lignocaine N-oxide was found in the perfusion fluid from the lignocaine 
perfused hearts under normal or anoxic conditions. A physiological difference was 
observed between control (Tyrode's solution), lignocaine and the lignocaine N-oxide 
perfused rat hearts under anoxic conditions. Normally an isolated perfused rat heart 
beats for only 1-2 min after stopping the oxygen supply, this was observed in the 
control and lignocaine perfused rat hearts, whereas the lignocaine N-oxide perfused 
hearts were found to beat for a further 6-8 min after stopping the perfusion of oxygen. 
3.2.4 Lignocaine N-oxide metabolism following intraperitoneal 
administration to the rat 
The fate of lignocaine N-oxide following i.p. administration to a healthy male rat was 
investigated. Urine samples (24 hr) were collected from the lignocaine N-oxide dosed 
rat (3.07 mg). The amount of lignocaine N-oxide and lignocaine collected in the urine 
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Table 3-4 Comparison of lignocaine N-oxide metabolism in normal and anoxic isolated 
perfused rat hearts. 
Compound Amount detected (n mole! g of heart) 
Perfused heart Non-perfused heart 
lignocaine N-oxide 129 71.0 
lignocaine o 61.S 
lignocaine N-oxide Uptake* 129 132.5 
Perfused (oxic) and non-perfused (anoxic) rat hearts were prepared as described in section 
2.3.7. 
* Following pertllsion oflignocaine N-oxide (500 ~M) to an isolated perfused heart (see 
section 2.3.7, the amount of drug uptake by the heart tissue was presumed to be the 
dddition sum oflignocaine N-oxide plus lignocaine detected. 
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was 3.10 mg and 0.18 mg, respectively. This gave a recovery of lignocaine and 
lignocaine N-oxide of 100.9% and 5.7% respectively of the dosed lignocaine N-oxide. 
No interfering peaks were detected in the HPLC chromatograms. There was no 
detectable degradation of lignocaine N-oxide when it was stored at room temperature 
in rat urine for 24 hours. The total amount of lignocaine and lignocaine N-oxide 
recovered was over 100%. This cause of this deviation is unknown. Further 
investigation using more replicates (rats) and better control of sample handling may 
be required. 
3.2.5 Lignocaine N-oxide metabolism in pbenotyped human 
microsomes and in isolated rabbit myocytes 
The metabolism of lignocaine N-oxide in a panel of human liver micro somes is shown 
in Table 3-5. Lignocaine N-oxide was selectively metabolised by several phenotyped 
human microsomes. According to the data analysis by Dr. Colin Henderson (lCRF, 
Dundee) using the Spearman correlation, no correlation was demonstrated between a 
specific P450 isoform and lignocaine N-oxide reduction. 
No reduction was observed in the anaerobic incubation of lignocaine N-oxide with the 
isolated rabbit myocytes. 
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Table 3-5 Lignocaine N-oxide metabolism using phenotyped human liver 
mlcrosomes 
Human liver microsome lignocaine N-oxide detected (%) lignocaine detected (%) 
IV 80.5 9.8 
V 91.6 32 
VII 61.0 J 1.0 
VIII 81.4 26.5 
IX 92.0 00 
X 89.6 2.3 
XI 97.3 0.0 
XI[ 90.2 0.4 
XIII 34.6 63.3 
XIV 93.7 2.1 
WI 59.5 38.4 
BI 71.7 117 
Experimental details were as described in section 2.3.8. 
Each panel ofphenotyped human liver microsomes containing different levels of 
cytochrome P450 isoforms. The human liver microsomes and data analysis·came rrom 
Dr. Colin J. Henderson. Imperial Cancer Research FumJ. Mol. Pharm·. Unit, 
Biomedical Research Center, Ninewells Hospital & Medical School, Dundee. 
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3.3 Mechanistic studies of lignocaine N-oxide reduction 
3.3.1 Effect of selected inhibitors on lignocaine N-Oxide 
metabolism in rat liver and heart tissue 
The effect of various inhibitors on the reduction of lignocaine N-oxide was studied in 
order to verify that the reduction process was enzymically mediated. As shown in 
Table 3-6 carbon monoxide totally inhibited lignocaine N-oxide reduction in both 
NADPH supplemented rat liver microsomes and heart S9 fractions. Under aerobic 
conditions, lignocaine N-oxide reduction were decreased substantially in both rat liver 
microsomes and heart S9 fractions. In rat liver microsomes potassium cyanide 
treatment or denaturing the protein completely inhibited N-oxide reduction. However, 
in rat heart S9 fraction, these treatments diminished but did not abolish lignocaine 
reduction. When lignocaine (200 f..lM) was added to rat microsomes prior to 
measuring lignocaine N-oxide metabolism, the amount of N-oxide metabolised 
decreased from 63.50/0 to 33.5%. 
3.3.2 Spectral studies of lignocaine N-oxide and lignocaine 
binding to rat liver microsomes 
Rat liver microsomes in a reduced and an oxidised state were used to examine the 
binding between substrate (lignocaine N-oxide or lignocaine) and microsomal 
cytochrome P450. 
Spectral changes induced by lignocaine N-oxide and lignocaine binding to the 
oxidised and reduced rat liver microsomes were recorded between 350 nm and 500 
nm. 
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Table 3-6 Effect of various treatments on lignocaine N-oxide reduction in NADPH 
supplemented rat liver microsomes and rat heart S9 fraction. 
Inhibitors Lignocaine N-oxide reduction (%) 
liver microsomes heart s9 fraction 
Nitrogen 63.5±2.0 87.2±1.7 
Air J 5.3±2.4 22.7±2. J 
Carbon monoxide ° 0 
Heat denatured tissue ° 47.4±3.5 
KeN (100'tM) ° 33.5±1.3 
Lignocaine (200,lrvl) D.8± I. J (Not determined) 
All procedures were carried out following experimental details as described in section 
2.4.1. All results are the mean ± standard deviation of three replicates. 
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In the oxidised microsomes, lignocaine N-oxide and lignocaine produced similar 
difference spectra with a trough at 417 nm as shown in Figure 3-18 and Figure 3-19. 
Figure 3-20 and Figure 3-21 show the difference spectra recorded from the addition of 
lignocaine N-oxide and lignocaine to the reduced rat liver microsomes. Spectral 
changes with the maximum absorbance at 410 nm and at 426 nm were shown for both 
lignocaine and lignocaine N-oxide. 
The spectral changes of lignocaine N-oxide and lignocaine in either oxidised or 
reduced microsomes are consistent with the typical spectrum of Type I binding of 
cytochrome P450. 193 
From Figure 3-22 A and Figure 3-23A, the magnitude of the substrate-oxidised 
microsomes binding spectra has been shown to be proportional to the concentrations 
of lignocaine N-oxide or lignocaine. The spectral dissociation constants (Ks) of 
lignocaine and lignocaine N-oxide binding to either oxidised or reduced microsomes 
were determined using the Lineweaver-Burke linear transformation. From the data of 
lignocaine and lignocaine N-oxide binding to the oxidised microsomes (Figure 3-
22B), the values for Ks were determined to be 137.13 J.!M and 250.34 J.!M, 
respectively. From the data of lignocaine and lignocaine N-oxide binding to the 
reduced microsomes (Figure 3-23B), the values for Ks were determined to be 21.54 
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Figure 3-18 Visible difference spectra of lignocaine N-oxide and oxidised rat liver 
microsomal suspensions. Lignocaine N-oxide concentrations were 0,0.02,0.04,0.06, 
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Figure 3-19 Visible difference spectra of lignocaine and 
oxidised rat liver microsomal suspensions. Lignocaine 
concentrations were 0, 0.02, 0.04, 0.06, 0.08, 0.10, 0.12, 0.14 and 
0.16 mM. Experimental details were as described in section 2.4.2. 
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Figure 3-20 Visible difference spectra of lignocaine N-oxide and reduced rat liver 
microsomal suspensions. Lignocaine N-oxide concentrations were 0,2,4,6, 8 and 10 
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Figure 3-21 VisibJe difference spectra of lignocaine and 
reduced rat liver microsomaJ suspensions. Lignocaine 
concentrations were 0, 2,4, 6, 8, 10 and 12 Jll''1. ExperimentaJ 
details were as described in section 2.4.2. 
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Figure 3-22 (B) Lineweaver-Burk plot of lignocaine N-oxide and lignocaine 
concentrations against the magnitudes of the difference spectrum in oxidised rat liver 
"microsomes. Experimental details were as described in section 2.4.2. 
Linear regression equation : 
lignocaine 
lignocaine N-oxide 
Correlation coefficient (.-2): 
y = 46503.206X + 33C).111 
Y = 70100.561X f 280.026 
lignocaine 0.QS3 
lignocaine N-oxide 0.985 
Spectral dissociation constant (Ks): 
lignocaine 137. I3 ~lM 
lignocaine N-oxide 250.34 ~lM 
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Figure 3-23 (A) Effect of lignocaine N-oxide and lignocaine concentration on the 
magnitude of the difference spectrum (6.500nm-41 Onm) in reduced rat liver microsomes. 
Experimental details were as described in section 2.4.2. 
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Figure 3-23 (B) Lineweaver-Burk plot of lignocaine N-oxide and lignocaine 
concentrations against the magnitudes of the difference spectrum in reduced rat liver 
microsomes. Experimental details were as described in section 2.4.2. 
Linear regression equation : 
lignocaine 
lignocaine N-oxidc 
Correlation coefficient (~): 
Y = 76.979X + 3.574 
Y = 13.206X +- 9108 
lignocaine 0.99? 
lignocaine N-oxide 0.991 
Spectral dissociation constant (Ks): 
lignocaine 21.54 ~tM 
lignocaine N-oxide 1.45 ~lM 
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3.3.3 Lignocaine N-oxide reduction in microsomes prepared 
from cobalt dosed rats 
The amounts of cytochrome P450 and bs in control and cobalt treated rat liver 
microsomes were measured. Administration of cobalt decreased the amount of both 
cytochrome P450 and bs, from 2.2 to 0.9 and 3.67 to 2.25 (n mole fmg protein), 
respectively, however lignocaine N-oxide was metabolically reduced in liver 
micro somes prepared from both control and cobalt treated rats. After an anaerobic 
incubation of 40 min, lignocaine N-oxide reduction in control rat liver micro somes 
was 63%; in the cobalt treated rat liver microsomes it was 45% (Figure 3-24). 
Therefore metabolism of lignocaine N-oxide was diminished as the content of 
cytochrome P450 and bs decreased. 
3.3.4 Reduction of lignocaine N-oxide in the presence of P450 
reductase, haem oxygenase or xanthine oxidase 
Lignocaine N-oxide is quantitatively converted into lignocaine when incubated under 
anaerobic incubation for 60 min in the presence of cytochrome P450 reductase, 
haemin and NADPH (Table 3-7). Incubation in the absence of cytochrome P450 
.reductase NADPH or haem resulted in no lignocaine N-oxide reduction. Lignocaine , 
N-oxide was fully reduced by xanthine oxidase with or without the supplement of 
haem. The reduction of lignocaine N-oxide was shown to be independent of human 
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Figure 3-24 Anaerobic incubation of lignocaine N-ox.ide in NADPH 
supplemented cobalt chloride treated and untreated rat liver microsomcs: 
(A) reduction of lignocaine N-oxide (8) formation of lignocaine. 
Experimental details were as described in section 2.4.3. 
Results are the mean ± s.d. of three determinations. 
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Table 3-7 Effect of haem, NADPH, haem oxygenase and cytochrome P450 
reductase on lignocaine N-oxide metabolism 
Incubation mixtures 
Component added 1 2 3 4 5 6 7 
lignocaine N-oxide " " " " " " " (100 ~) 
I 
I 
cytochrome P450 reductase - I " " " I " I I - -(3 nmole) I I I 
Haemoxygenase " - " " " - i I -(0.7 nmole) 
haem (40 J.lM) " " " - " " -I i 
NADPH (200 J.lM) " r " " ! " I - " " I I 
xanthine oxidase( 1 unit) I 
j I I " - I - - I - I - " I I I I I 
Results: 1 i i ! 
Percentage of lignocaine 
I I I 
none I 100% 
I 
100% I none none 100% 100% 
N-oxide reduction after 1hr 
I 
I 
of anaerobic incubation. 
I 
I 
All procedures were carried out following experimental details as described in section 
2.4.4. All results are the mean ± standard deviation of three replicates. 
"--.)" Indicates the components present in the total incubation mixtures. 
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3.4 Non-enzymic reduction of lignocaine N-Oxide 
3.4.1 Lignocaine N-oxide reduction by myoglobin and 
haemoglobin 
Lignocaine N-oxide was anaerobically incubated with deoxymyoglobin and 
metmyoglobin to investigate the effect of myoglobin oxidative state on lignocaine 
N-oxide reduction. Lignocaine N-oxide was 46% metabolised to lignocaine in the 
presence of deoxymyoglobin after an anaerobic incubation of 2 hr (Figure 3-25). No 
reduction was detected in the presence of metmyoglobin. Lignocaine N-oxide 
reduction by deoxymyoglobin solution was demonstrated to be inhibited by oxygen 
(Figure 3-26). As the oxygen content increased from 0 to 3.5%, the amount of 
lignocaine N-oxide reduction decreased from 44.8% to 6.6% following a 2 hour 
incubation; lignocaine N-oxide reduction being completely inhibited when oxygen 
concentration was 5% or greater. 
No reduction was observed during the anaerobic incubation of lignocaine N-oxide 
with either deoxyhaemoglobin or methaemoglobin with the supplement ofNADPH. 
Lignocaine N-oxide reduction by inorganic iron and 
haem 
From Table 3-8 it can be seen that lignocaine N-oxide was quantitatively converted 
into lignocaine by haemin in the presence of ascorbic acid~ whilst only a minor 
amount (5%) of lignocaine N-oxide was reduced by haemin-NADPH combination. 

























lignocaine N-oxide reduction with deoxymyoglobin 
lignocaine formation with deoxymyoglobin 




Figure 3-25 Anaerobic incubation of lignocaine N-oxide with 
deoxymyoglobin and metmyoglobin. Experimental details as described in 
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Hgure 3-26 Effect of oxygen tension on the reduction of 
lignocaine N-oxide by deoxymyoglobin. Experimental details as 




Table 3-8 Effect ofNADPH, iron, haemin and ascorbic acid on hgnocaine N-oxide 
metabolism. 
Component added Incubation mixtures 
lignocaine N-oxide v' v' v' v' v' (100 ~lM) 
Fe2+ (I mM) 
Fe3+ (I mM) 
EDTA (I mM) 
haemin (I mM) 
ascorbic acid (I mM) 
NADPII (I mM) 
lignocaine N-oxide 
reduction (%) () () () () 0 () 100 5 () () 
All procedures were carried out following experimental details as described in section 
2.4.7. All results are the mean ± standard deviation of three replicates. NADPH was 
prepared from NADPH generating system as described in section 2.2.2. 
'.'....j" indicates the components present in the total incubation mixtures. 
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3.4.3 Electron spin resonance spectroscopy studies of 
lignocaine N-oxide in the presence of myoglobin 
ESR spectroscopy in combination with the spin trapping agent, 5,5-dimethyl-l-
pyrroline N-oxide (DMPO), was used to investigate further the mechanism of 
lignocaine N-oxide reduction mediated by myoglobin. 
In order to assist interpretation of the spin trap data from lignocaine N-oxide reduction 
by myoglobin, model systems were first used to identify possible DMPO radical 
species. With a suitable oxidising system (see Figure 3-27), the hydroxyl radical 
(OH-) DMPOIOH- (1:2:2: 1 spectrum with hyperfine splitting constants, AN = AH 
=14.9 G) and the carbon centred alkyl radical (CH3- or R-) DMPOI R- (1: 1: 1: 1: 1:1) 
ESR spectrum with hyperfine splitting constants, AN=16.2 G, AH =23.0 G) spin 
adducts were observed (See Figure 3-27 A and B). These results were consistent with 
previous studies using DMPO to trap hydroxyl and alkyl free radicals. 194 Further 
evidence that these spectra were derived from reactive oxygen is shown by loss of the 
DMPOIOH- ESR spectrum when superoxide dismutase (SOD) and catalase were 
added (Figure 3-27 C). SOD and catalase will compete with DMPO for reactive 
oxygen. 3 
In the anaerobic incubation of lignocaine N-oxide and deoxymyoglobin, a DMPOX 
(5,5-dimethylpyrrolidone-2-oxy-1) and DMPO/R- ESR spectrum were both observed 
(see Figure 3-28 B). 
MhPe(ll)+ DMPO + lignocaine N-oxide ----f DMPOIR. + DMPOX + MbFe(lII) (final product) 
The DMPOX ESR signal was shown to decrease with time, whilst the DMPO/ R-
spectrum appeared to persist over a 10 minute period. Under anaerobic conditions, no 
spin trapped ESR spectrum was detected from deoxymyoglobin alone (Figure 3-28 
A), lignocaine and deoxymyoglobin (Figure 3-28 D) or metmyoglobin and lignocaine 
N-oxide (Figure 3-28 G). Also, no ESR signal was observed in the presence of 







Figure 3-27 The 5,5-dimethyl-l-pyrroline N-oxide (OMPO) spin adduct 
electron sp·in resonance spectra of: 
A. DMPOIOH- ... Fe2+ + EDTA + H20 2 + DMPO 
B. DMPO/Cfh or DMPO/R· <} Fe2+ + EDTA + H20 2 +DMSO + DMPO 
C. FeS0
4 




+ DMPO + superoxide dismutase + catalase 
Experimental details were as described in section 2.4.8. 
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Figure 3-28 The 5,5-dimethyl-l-pyrroline N-oxide (DMPO) spin adduct 
electron spin resonance spectra of: 
A. deoxymyoglobin+ DMPO 
B .. deoxymyoglobin+DMPO+lignocaine N-oxide anaerobically incubated at J 7 °C at O. 
at 1,5 and 10 minutes DMPOX t-DMPO/R· 
C. deoxymyoglobin +lignocaine N-oxide +SOD+catalase+DMPODMPO/R· 
D. deoxymyoglobin + DMPO + lignocaine' 
E. deoxymyoglobin +Iignocaine N-oxide+DMPO (air) 
F. deoxymyoglobin +Iignocaine +DMPO (air) 
G. metmyoglobin+ DMPO+lignoca i ne N-oxide 
H. deoxymyoglobin+methylamine+DMPO. DMPOX+DMPO/R-
AU experiments were operated under anaerobic conditions except E and F. ESR 




(Figure 3-28 E and F). However, a similar mixture ofESR spectra (DMPOX and 
DNfPO/ R
e
) was observed with methylamine and deoxymyoglobin under anaerobic 
condition (Figure 3-28 H). The significance of this will be discussed later. 
The ESR spectrum ofDNfPOX was identified previously and is the result of direct 
oxidation ofDMPO. 195 
MbFe(lII) + DMPO + Hydrogen peroxide -+ DMPOX + MbFe(1V) =0 
Further evidence for a myoglobin mediated oxidation ofDMPO to the DMPOX 
species was obtained using oxidation of metmyoglobin with hydrogen peroxide. This 
resulted in foonation of a characteristic DMPOX ESR spectrum consisting of a triplet 
of doublets with hyperfine coupling constants AN =7 G, AH =4 G (see Figure 3-29 A). 
A characteristic DMPO/OH
e 
spin adduct was detected in the presence of ferryl 
myoglobin [Fe(IV)=O] (prepared free from metmyoglobin as described in section 
2.1.4) with or without the addition of lignocaine (See Figure 3-29 B and D). When 
lignocaine N-oxide or dimethylsulphoxide (DMSO) was added to the ferryl 
myoglobin and DMPO, a mixed spectrum ofDMPO/Re and DMPO/OH
e 
spin adducts 
was recorded (Figure 3-29 C and E). 
Fe(lV)=O + DMPO + lignocaine N-oxide (or DMSO) -+DMPOIR' + DMPOIOH' +MbFe(llI) 
The DMPO/OH spectrum is likely to be a direct result ofDMPO trapping a hydroxyl 
radical liberated as ferryl myoglobin is oxidised to metmyoglobin. The ferryl 
myoglobin or its liberated hydroxyl radical will also react with a suitable hydrogen 
donor such as DMSO (see Figure 3-29 E) to liberate an alkyl radical that is trapped by 
DMPO as DMPO/ OI1. Lignocaine-N-oxide appears to react in a similar way with 
ferryl myoglobin (see Figure 3-29 C) since both lignocaine-N-oxide and DMSO result 
in DMPO/Re adducts. The implications of this will be discussed later (section 4.3). 
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A. metmyoglobin+Hz02+ DMPO 
B. ferryl myoglobin+DMPO .. . . . 
.J\ ",-".,.0\ /\ .. ,,--j\~v... 
C. ferryl myoglobin+DMPO+ lignocaine N-oxide V ~ ..,.. - ~ • 
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Figure 3-29 The 5,5-dimethyl-l-pyrroline ,N-oxide (DMPO) spin adduct 
electron spin resonance spectra of: 




ferry I myoglobin t-DMPO; 
ferry I myoglobin+DMPO+ lignocaine N-oxide 
ferryJ myoglobin+DMPO+lignocaine 
E. DMPO/OH·+DMPO/R. ferryl myoglobin+DMPO+DMSO. 
All experiments were operated under anaerobic condition. ESR condition and 






3.4.4 Spectral binding studies of lignocaine N-oxide with 
myoglobin 
Myoglobin has a characteristic absorbance spectrum in the visible region in the 
absence of oxygen. Spectral changes were observed for deoxymyoglobin and 
metmyoglobin in the presence of lignocaine N-oxide and lignocaine. As seen in 
Figure 3-30 and 3-31, the binding of either agents to myoglobin produced a difference 
spectra in wavelength from 250 to 440 run, while the spectrum between 440 run to 
600 run remained unchanged. The binding of lignocaine N-oxide and lignocaine to 
deoxymyoglobin produced a hypsochromic shift at 418 run; a hypochromic shift for 
lignocaine and a hyperchromatic shift for lignocaine N-oxide at 355 run (Figure 3-30). 
As shown in Figure 3-31, the binding of met myoglobin to lignocaine N-oxide 
produced a hyperchromic shift, whilst the binding to lignocaine produced a 
hypochromic shift at 410 nm. The binding of ferryl myoglobin to lignocaine N-oxide 
and lignocaine both produced hyperchromic shifts in the absorbance at 288 run as 
shown in Figure 3-32. These changes of absorption intensity indicate the binding 
between lignocaine and lignocaine N-oxide with myoglobin. 
The DV/visible difference spectrum observed following an anaerobic incubation of 
lignocaine N-oxide with deoxymyoglobin at 37 0 C for 60 min along with the 
lignocaine N-oxide and deoxymyoglobin binding spectra is shown in Figure 3-33. 
Incubation of lignocaine N-oxide with deoxymyoglobin results in a diminution of the 
.myoglobin spectral peaks at 544 and 582 nm with a concomitant increase at 418 nm. 
Figure 3-34 shows the changes in absorbance at 580 run that occurred when several 
tertiary amine N-oxides were anaerobically incubated with deoxymyoglobin for 2 hr. 
Lignocaine N-oxide, amiodarone N-oxide, diltiazem N-oxide and disopyramide 
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Figure 3-30 UV/visible difference spectra for deoxymyoglobin 
binding with lignocaine N-oxide and lignocaine. Experimental details were as 
described in section 2.4.9 
*No spectral difference was observed in the deoxymyoglobin spectrum between 440 
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Figure 3-31 UY/visible difference spectra for metmyoglobin and metrnyoglobin 
binding with lignocaine N-oxide and lignocaine. Experimental details were as 
described in section 2.4.9. 
*No spectral difference was observed in the metmyoglobin spectrum between 440 to 
.660 run in the presence of lignocaine or lignocaine N-oxide. 
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Figure 3-32 UV Ivisible difference spectrum for ferryl myoglobin 
binding with lignocaine N-,oxide or lignocaine. Experimental details were as 
described in section 2.4.9. 
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Figure 3-33 UV/visible difference spectrum for deoxymyoglobin alone; and 
deoxymyoglobin incubated anaerobically with lignocaine N-·oxide at 37°C after 1 
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Figure 3-34 Absorbance observed at 580nm when lignocaine N-oxide, amiodarone 
N-oxide, diltiazem N-oxide or disopyramide N-oxide were incubated at 37°C under 
. anaerobic conditions with deoxymyoglobin. Experimental details as described in section 
2.4.9. 
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Chapter 4 Discussion 
Sudden cardiac death has been a major medical issue for four decades. 196 
Cardiovascular arrhythmias are exceedingly complex and the therapeutic utility of 
most available antiarrhythmic drugs is limited either by lack of consistent efficacy or 
by the potential for serious side effects. Lignocaine is the drug of choice for the acute 
treatment of arrhythmias following cardiac arrest. 197 However, the short biological 
half-life, narrow therapeutic range and a rapid metabolic clearance have limited the 
use of lignocaine in the controlling of arrhythmias or preventing cardiac events. 198, 199 
There is a need for agents with prolonged action and less systemic toxicity, and 
pro drugs with heart specific activation would appear to fulfil this role. 
The possible use of aliphatic tertiary amine N-oxides as bioreductive agents in the 
chemotherapy of hypoxic regions has been extensively studied and reviewed by 
Patterson (1993).68 Patterson et al. also reported that aliphatic amine N-oxides of 
DNA intercalators with alkylamino sidechains such as bis-alkylamino substituted 
anthraquinone, anthrapyrazole and anthracene and mono-acridinone possess low 
aerobic toxicity can be metabolised to their potent cytotoxic parent compounds, the 
DNA binding and tertiary amines.67 These N-oxides of DNA affinic, cytotoxic 
agents can be bioreduced selectively in the hypoxic tumour cells are recognised as 
. lb' d . dru 200 potentia lOre ucttve gs. 
Ischaemic heart tissue is well recognised as a region of transient hypoxia. 201 The 
ability of hypoxic cardiac tissue to convert antiarrhythmic N-oxide prodrugs into 
active tertiary amines was proposed and studied using lignocaine N-oxide as a model 
compound. The myocardial, hepatic and systemic metabolism of lignocaine and its 
mechanism of reduction was studied in detail to assist the evaluation of the suitability 
of lignocaine N-oxide as an antiarrhythmic prodrug. 
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metabolites 
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Given that lignocaine N-oxide metabolism had not previously been described, a novel 
HPLC analytical method was developed here to give simultaneous separation, 
identification and quantification of the highly polar lignocaine N-oxide; and the 
aliphatic amine bases lignocaine and monoethylglycine xylidide (MEGX), an 
anticipated polar metabolite of lignocaine, in various biological matrices. Aliphatic 
tertiary amine N-oxides are highly polar which would partly account for difficulties in 
their detection and analysis in biological samples, since they are extracted poorly by 
many organic solvents, partition poorly into chromatographic stationary phases and 
can be thermolabile. 178 A rapid, simple acid-acetonitrile deproteinationiextraction 
sample pre-treatment procedure prior to a reversed-phase HPLC system has been 
applied in the routine study of the fate of lignocaine N-oxide in tissues, subcellular 
fractions, cells, urine and non-biological samples. This method was showed to be 
stable, sensitive and reproducible and provided good recovery of lignocaine N-oxide 
and its metabolites of interest to this study. 
Reversed-phase HPLC which is capable of polar compound analysis has also been 
used for the analysis of other N-oxides including chlorpromazine N-oxide, 
amitriptyline N-oxide, and imipramine N-oxide in in vivo metabolism studies. 113, 116, 
184,202,203,204,205 
Detection of metabolites in lignocaine N-oxide metabolism 
All samples analysed in the HPLC analysis as described in Chapter 2 were examined 
against standards of lignocaine N-oxide, glycine xylidide (GX) and MEGX 
throughout the study. Lignocaine was the only detected metabolite found in 
lignocaine N-oxide metabolism under anaerobic conditions. The metabolism of 
. ddt 41, 
lignocaine has been extensively studied and was reported to be speCIes epen en . 
35,206,207,208 The main reactions described are N-deethylation, hydrolysis and ring 
hydroxylation. 209 Lignocaine is metabolised via hydroxylation of the aromatic ring 
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and the methyl group to give MEGX and 3-hydroxy lignocaine in human hepatic 
microsomes. In rat hepatic microsomes, lignocaine is sequentially metabolised to 
J\1EGX and GX.209 In this study, no MEGX, GX or 3-0H lignocaine was detected in 
rat liver (subcellular fractions), rat heart (cellular, tissues, whole heart and perfusates), 
urine of lignocaine N-oxide i.p. dosed rats, rabbit myocytes or human liver P450 
phenotyped microsomes. 
Evidence of the formation of lignocaine N-oxide 
The formation of N-oxides from aliphatic tertiary amine functional groups has been 
reported to be a major metabolic pathway for many tertiary amine compounds. 71,210, 
211 Patterson et al identified lignocaine N-oxide from an incubation of lignocaine with 
NADPH supplemented rat liver microsomes but as a very minor metabolite. 177 In this 
report, lignocaine N-oxide was extracted from the microsomes, separated by TLC and 
was identified using chemical ionisation mass spectrometry (CIMS). This is the only 
report relating to lignocaine metabolism to lignocaine N-oxide, an extremely water 
soluble Phase 1 metabolite. 
4.2 Metabolism of lignocaine N-oxide 
4.2.1 Enzymology of lignocaine N-oxide reduction in liver 
The metabolism of lignocaine N-oxide was first studied in liver since it is a rich 
source of drug metabolising enzymes including cytochrome P450s. 
Lignocaine N-oxide metabolism in rat liver microsomes 
The occurrence and mechanism of lignocaine N-oxide reduction to lignocaine has not 
been investigated previously. It was established that lignocaine N-oxide can be 
quantitatively reduced to lignocaine by NADPH supplemented rat liver microsomes 
under hypoxic and anoxic conditions. No other metabolites (e.g. lV-dealkylation to 
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MEGX) were detected following incubations oflignocal'ne und d' . 
er con Ihons of 
hypoxia up to one hour (Figure 3-5). This N-oxide reduction reaction was NADPH 
dependent, sensitive to oxygen, and was inhibited by carbon monoxide and cyanide. 
This suggests a NADPH dependent N-oxide reductase, cytochrome P450 mixed 
function oxidase, may be responsible for lignocaine N-oxide metabolism in rat liver 
microsomes. The requirement for a native enzyme involvement in lignocaine N-oxide 
reduction was demonstrated by the total inhibition of lignocaine formation after heat 
denaturation of microsomes. 
Substrate binding of lignocaine to rat liver mlcrosomes 
The interaction between lignocaine N-oxide and either oxidised or reduced rat liver 
microsomal suspensions showed a typical type I spectral changes (417 nm). This 
suggests lignocaine N-oxide may interact with the protein moiety of the cytochrome 
P450 haemoprotein. There was no evidence (type II difference spectrum) to support 
the direct coordination of lignocaine N-oxide to the reduced haem iron (Fe 2+) of 
cytochrome P450. 154, ~59, 160, 161, 162 
Lignocaine, also known to be metabolised by P450 enzymes,209 produced similar 
type I difference spectra with the oxidised and reduced rat liver microsomes. As 
shown in Figure 3-22 and 3-23, the maximum absorbance of all substrate-rat liver 
microsomes binding spectra were proportional to the substrate concentrations. In rat 
liver microsomes, lignocaine N-oxide seems to have more binding to the reduced 
microsomes (Ks =1.5 JlM) than oxidised microsomes (Ks =250 J,lM). This result is 
further supported by the similar Km value calculated from the enzyme kinetics of 
lignocaine N-oxide in the rat liver S9 fractions (250 J.!M see section 3.2.2). 
Lignocaine N-oxide metabolism by phenotyped human liver microsomes 
Human liver microsomes contain multiple forms ofP450 and genetic polymorphisms 
are recognised in drug metabolism.212 A panel of phenotyped human liver 
microsomes containing different ratios of cytochrome P450 isozymes were used to 
investigate the correlation between lignocaine N-oxide reduction and cytochrome 
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P450 isozymes. Lignocaine N-oxide was showed to be reduced by some of the 
phenotyped microsomes under anaerobic conditions Lignocaine N ·d d . . -ma e re uctlOn, 
unlike lignocaine dealkylation known to be catalysed by CYP3A4, showed no 
correlation to any specific cytochrome P450 isoforms. This result suggested a wide 
range of isoforms might be responsible for N-oxide reduction and the possible 
occurrence of lignocaine N-oxide reduction in humans. 209 Unlike AQ4N, which is 
reduced by the CYP2C8 and CYP3A family, there may not be a specific active site of 
cytochrome P450 isoforms for lignocaine N-oxide.213 
Enzymology of lignocaine N-oxide reduction in liver -role of cytochrome P450 
According to this study, lignocaine N-oxide reduction in rat liver microsomes is 
enzymic and is mediated by cytochrome P450 in the liver. This is supported by the 
direct N-oxide reduction of lignocaine N-oxide with purified cytochrome P450 
reductase in the presence of haem. 
Previous work relating to several tertiary amine N-oxide reduction including tiaramide 
N-oxide, imipramine N-oxide and dimethylaniline N-oxide has been described by 
Kato et al. 108, 109,214 They suggested that under anaerobic conditions in the presence 
of either NADH or NADPH, these N-oxides may be metabolised to amines by liver 
homogenates, micro somes or cytochrome P450. The microsomal NADPH dependent 
N-oxide reductase was induced by phenobarbitone, was oxygen sensitive and 
inhibited by carbon monoxide, n-octylamine and various P450 inhibitors. The results 
of the present study support the suggestion that cytochrome P450 is involved in 
N-oxide reduction. Iwasaki et al. studied tiaramide N-oxide reduction using a 
reconstituted purified cytochrome system that provided some proof of the ability of 
cytochrome P450 mediated N-oxide reduction and identified the direct binding of 
N-oxide to the cytochrome haem. 11O The present study shows that lignocaine N-oxide 
metabolism is directly correlated to cytochrome P450. Cytochrome bs and 
cytochrome P450 level were both significantly decreased by cobalt treatment which 
correlated with inhibition of reduction. 
The above results established the feasibility of lignocaine N-oxide reduction under 
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hypoxic conditions and indicated the involvement of cytochrome P450 under the 
requirement for low oxygen concentration. 
Lignocaine N-oxide reduction in cobalt treated rat liver microsomes and haem 
oxygenase 
Lignocaine N-oxide metabolism was inhibited as the cytochrome P450 level was 
suppressed in the liver microsomes prepared from the cobalt i.p. dosed rats. Haem 
oxygenase, a microsomal enzyme capable of haem metabolism was concomitantly 
induced by the cobalt treatment. Haem metabolism is a main pathway for the removal 
of haem during the turnover of haemoproteins such as haemoglobin, myoglobin and 
cytochrome P450s and thus will reduce the cellular haem level. 
Haem oxygenase is known as one of the heat shock proteins (HSP), a group of 
intracellular proteins which confer a protective effect during stress and are 
upregulated by heat and other physiological stress factors including free radicals and 
inflammatory mediators. 169 The induction ofHSP during oxygen stress was reported 
in myocardial ischaemiaireperfusion,215 kidney hypoxia and tumour hypoxia with the 
reduction of cellular haem level. Haem oxygenase that can be induced by a variety of 
stimulants-Co, Cd, Zn, Sn, haem and hormones, has two isoforms- HO-l and 
HO_2.173 The HO-l gene that has heat shock regulatory elements, can be induced in 
vivo up to 100 fold during oxidative stress, is responsible for the decrease of total 
hepatic P450 levels. 165 
Haem oxygenase is not a haemoprotein, instead it will bind to haem in a 1: 1 molar 
ratio as a transitory haemoprotein, and requires microsomal NADPH-cytochrome 
P450 reductase in the haem oxidation process. Haem degradation products, i.e. bile 
pigments, were reported to be antioxidants and free radical scavengers that can protect 
tissue damage from oxygen stress. 168 Haem oxygenase has an absolute requirement 
for NADPH and dioxygen, can serve as a mono-oxygenase and can be inhibited by 
carbon monoxide. Under anaerobic conditions, lignocaine N-oxide can be reduced to 
lignocaine by cytochrome P450 reductase, haem and NADPH with or without haem 
oxygenase. This suggests that haem oxygenase is not responsible for lignocaine 
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N-oxide reduction in the ischaemic/hypoxic heart but may st1'11 b' 1 d' e mvo ve man 
endogenous protective mechanism for oxygen stress in the heart It' . t . 
. IS m erestmg to 
speculate that lignocaine N-oxide could not bind to haem within the HO catalytic site 
due to the presence of carboxylic acid groups from amino acids flanking the haem 
pocket. The negative charge on these carboxylic acids may repel W -0- moiety of 
lignocaine N-oxide. 
4.2.2 Lignocaine N-oxide metabolism in the heart 
Lignocaine N-oxide metabolism in the rat heart 
The potential of lignocaine N-oxide as an antiarrhythmic prodrug was first determined 
by the metabolism of this agent in hypoxic heart homogenate. Lignocaine N-oxide 
was quantitatively metabolised to lignocaine in rat heart homogenate and S9 fraction, 
composed of heart cytosol and sarcoplasmic reticulum, under anaerobic conditions 
with the supplement ofNADPH. Lignocaine was the only metabolite found in the 
lignocaine N-oxide reduction study in anaerobic rat hearts. No further lignocaine 
metabolism was detected in an anaerobic incubation of lignocaine with rat heart 
homogenate up to 90 minutes (Figure 3-5). 
A significant decrease (40%) in lignocaine N-oxide reduction after heat denaturation 
of heart S9 fraction demonstrated the importance of enzyme/proteins in its 
metabolism. Inhibitors of haemoprotein mediated reduction including oxygen, carbon 
monoxide and cyanide produced a considerable decrease of lignocaine N-oxide 
reduction in rat heart S9 fractions. The diminution of N-oxide reduction but not its 
complete abolition, suggests the existence of a non-enzymic pathway of lignocaine 
N-oxide reduction. The total inhibition of lignocaine N-oxide reduction by carbon 
monoxide indicates that all pathways to the reduction of the N-oxide require a haem 
centred iron. 
Reduction of lignocaine N-oxide in heart sarcosomes was not observed. This may 
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have been due to the low cytochrome P450 content in the sarcosomes although P450 
expression in heart has been poorly investigated. 174 The fact that lignocaine N-oxide 
was extensively reduced in the heart cytosolic fraction in the absence of . . au suggestmg 
that cytosol is an important site for lignocaine N-oxide reduction in myocardium. 
Lignocaine N-oxide reduction by purified bovine myoglobin 
Myoglobin is a globular protein with a molecular weight about 17,200 and 153 amino 
acids containing one protohaem.
216 
It is an intracellular haemoprotein that can 
reversibly bind oxygen and is found in high concentrations in red skeletal muscle and 
heart of most vertebrate species. In heart cytosol, myoglobin is a major 
haemoprotein. In this study myoglobin was shown to be capable of reducing 
lignocaine N-oxide to lignocaine under anaerobic conditions. Specifically a 
quantitative reduction of lignocaine N-oxide to lignocaine by purified bovine 
deoxymyoglobin under anaerobic incubation was measured by HPLC. The N-oxide 
reduction was highly oxygen sensitive with a total inhibition at oxygen tension of 5%. 
This was likely to be due to the high binding affinity of myoglobin for oxygen. In the 
lignocaine N-oxide reduction process, myoglobin was considered to act as an N-oxide 
reductase and carried out lignocaine N-oxide reduction in the anoxic heart. 
Unlike myoglobin, lignocaine N-oxide was not reduced by haemoglobin. This may be 
due to the structural difference between haemoglobin, a tetrameric haemoprotein, and 
myoglobin, a monomeric haemoprotein, preventing the accessibility of lignocaine 
N-oxide to the haem sites in the tetrameric protein. 
No studies relating to myoglobin and aliphatic tertiary amine N-oxide reduction under 
reducing conditions have been reported previously. Gorrod and Patterson have 
demonstrated that N,N-dialkylaniline N-oxides were reduced by haemoglobin.2l7 The 
N-oxides of N,N-dimethylaniline, N,N-dimethylamino-azobenzene, indicine and 
imipramine were reported to be reduced in whole red blood cells, or by 
oxyhaemoglobin. 101 ,106 It is obvious that due to the conformational difference, 
myoglobin appears to have a very different reaction mechanism to haemoglobin. 
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Non-enzymic reduction of lignocaine N-oxide 
The non-enzymic catalysis of lignocaine N-oxide to lignocaine in heart cytosol was 
further investigated using haemin, a basic haemoporphyrin, in the presence of 
inorganic iron. Lignocaine N-oxide was metabolised by haemin in the presence of 
both ascorbic acid and NADPH. Non-enzymic N-oxide reduction of indicine N-oxide 
and trimethylamine N-oxide by inorganic Fe2+ has been reported.2I8 However, 
lignocaine N-oxide reduction was not facilitated by Fe2+ or Fe3+ in the presence of 
ascorbic acid and NADPH. It is evident that lignocaine N-oxide can be metabolised 
through a non-enzymic pathway that contributes to more than half of lignocaine 
N-oxide conversion in the anaerobic rat heart cytosol. The possible mechanism of this 
is discussed in the next section. 
Lignocaine N-oxide reduction in the isolated rat heart 
Lignocaine N-oxide was found to be reduced to lignocaine in the isolated rat hearts 
under hypoxic conditions. This is the first time that evidence has been obtained 
relating to the tnyocardial reduction of lignocaine N-oxide in the intact heart. 
A significant amount (46%) of lignocaine N-oxide was reduced in the hypoxic/anoxic 
isolated rat heart. A steady (normal) cardiac rhythm was maintained in the undosed 
heart. Similarly, hearts perfused with lignocaine or lignocaine N-oxide maintained 
normal cardiac rhythms. A change from oxygenated, hypoxic to anoxic condition was 
produced by interrupting the perfusion flow. After cessation of the oxygenated 
perfusion medium, normal and lignocaine perfused isolated hearts stopped in 1-2 
minutes, whilst lignocaine N-oxide perfused isolated hearts had a prolongation of the 
heart beat for up to 8 minutes. Under normal (oxic) perfusion, no lignocaine was 
found in the perfusion fluid from lignocaine N-oxide perfused heart~ no lignocaine 
N-oxide was found in the perfusion fluid from the lignocaine perfused heart. 
Lignocaine derived from lignocaine N-oxide was found only in the anoxic heart. This 
suggests lignocaine N-oxide was metabolised selectively in the hypoxic/anoxic heart. 
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An in vivo study on lignocaine N-oxide was previously carried out in sheep by 
McIntosh and Kane in Strathclyde Institute for Drug Research (1991).176 The cardiac 
electrophysiological effects recorded in sheep hearts demonstrated that lignocaine 
N-oxide was not active under normal conditions, and showed that it was no less potent 
than lignocaine under simulated ischaemic conditions (p02 25-30 mmHg). 
The in vitro studies on lignocaine N-oxide perfused through controlled, isolated 
animal hearts suggested that lignocaine N-oxide has the potential of acting as a site-
specific antiarrhythmic prodrug that may be activated only in the ischaemic 
tissues/organs. 
Xanthine oxidase 
It is known that reperfusion of oxygen to ischaemic cardiac muscle can generate 
superoxide radicals and damage the heart.219 This injury is thought to be due to 
cytotoxic oxygen free radicals generated by xanthine oxidase. 18 Administration of 
allopurinol, a xanthine oxidase inhibitor, has been observed to diminish the amount of 
reactive oxygen damage to the heart.13 Lignocaine N-oxide was reduced by purified 
xanthine oxidase under anaerobic conditions. This was investigated since xanthine 
oxidase was previously showed to reduce other N-oxides. 80 Lignocaine, already a 
potent antiarrhythmic agent, is reported to be a hydroxy radical scavenger
220 
and this 
may contribute to the protective effects seen by this agent. Xanthine oxidase is a 
heart cytosolic enzyme so is likely to contribute to the total lignocaine N-oxide 
reduction observed in heart tissue. 
4.2.3 In vivo metabolism of lignocaine N-oxide 
Lignocaine N-oxide metabolism in vivo following its i.p. administration to a healthy 
rat showed less than 5% of the reduction product in the urine. The majority of 
N-oxide was excreted unchanged. This suggests that lignocaine N-oxide may be 
stable to metabolic reduction under oxic condition in vivo. 
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The in vivo metabolism of N-oxides has not been extensively studied. It has been 
recognised that compounds containing an aliphatic tertiary amine group may be 
oxidised to N-oxide metabolites; and these N-oxides can be reduced to their 
d · . 70, 71,117 E I tud' tr' hi' . correspon lng ammes. ar y s les on lmet y amme N-oXlde suggested 
thatN-oxide reduction of this compound is not a major route of metabolism. 84 
However, the in vivo metabolism of chlorpromazine N-oxide, amitriptyline N-oxide, 
indicine N-oxide and imipramine N-oxide demonstrated that tertiary amine N-oxides 
can be metabolised through N-dealkylation and hydroxylation as well as N-oxide 
reduction.1l3, 114, 115, 116 
Ideally as a site/diseased state activated prodrug, lignocaine N-oxide is expected to be 
reduced to lignocaine in hypoxic tissues/organs and remain unchanged in nonnal 
oxygenated tissues. In this study, lignocaine was not oxidised to lignocaine N-oxide 
in rat liver microsomes or heart homogenate under anaerobic condition. The systemic 
metabolism of lignocaine N-oxide is unknown. Further phannacokinetic and 
pharmacodymic studies under controlled or systemic ischaemic conditions might 




4.3 Mechanism of lignocaine N-oxide reduction 
Haemoprotein mediated lignocaine N-oxide reduction 
Previous sections have demonstrated that haemoproteins, including cytochrome P450 
and myoglobin, are capable of lignocaine N-oxide reduction under anoxic conditions. 
The absolute requirement for the absence of oxygen and the requirement ofNADPH 
highlights the importance of the reduced status of haem component. The inhibition of 
N-oxide reduction by oxygen, carbon monoxide and cyanide, as well as a direct 
N-oxide reduction by the reduced haemin further supports a role for the haem binding 
of lignocaine N-oxide as a prerequisite for its reduction. 
Mechanism of Lignocaine N-oxide reduction by P450 and other NADPH requiring 
haem based systems 
In this study cytochrome P450 and NADPH have been shown to mediate N-oxide 
reduction with lignocaine N-oxide behaving as an alternative oxygen source to 
molecular oxygen. The N-oxide reduction by myoglobin appears slightly different 
because no external reducing system is required. 
We postulate an oxygen atom transfer process between the N-oxide and haem centre. 
Figure 4-1 illustrates a proposed lignocaine N-oxide reduction by the haem centre of 
haemoproteins. First, a one electron reduction of the haemoporphyrin, [Fe(III) to 
Fe(II)] can be generated by NADPH via NADPH cytochrome P450 reductase. (i) The 
oxygen atom of lignocaine N-oxide is coordinated to the Fe(II) atom of the reduced 
haemoprotein. (ii) At this stage, the hydrophobic region of lignocaine N-oxide may 
also bind to the substrate binding domain of the protein and forms a haem[Fe(II)]-
N-oxide-protein complex. (iii) With the cleavage of the N-O bond, lignocaine (tertiary 
amine) and an oxy-ferryl haemoprotein, foxy-FeelY) pair], complex are formed. This 
ferryl intermediate can be represented as [Fe(II)-O], Fe4+_02- or [Fe(IV)=O]. In this 
case, the haem-[Fe(IV)]=O to give a net ionic charge of +2. (iv) Following the 
transfer of the second electron to the oxy-ferryl haemoprotein complex and the release 









Haem-FeIV=O - N-lignocaine 
( iii) t- lignocaioc 
Cyt P450 
Haem-FeIV =0 
Cyt P450 ~n( 
Haem-felli ~l Hzo 
Figure 4-1 Proposed lignocaine N-oxide reduction mechanism by haemoprotein: 
l. One electron reduction of haem Fe(ITI) to Fe(IT). 
11. TJIe formation of haem [Fe(IV)=Ol"""N-lignocaine complex. 
Ill" N-O bond cleavage to form a oxy-ferryl [Fe(IV)=O] haemoprotein intermediate and 
lignocaine. 
IV. Following a second electron transfer, the oxidised haemoprotein [Fe(III], lignocaine and 
water are fonned. 
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Previously, a mechanism for cytochrome P450 mediated tertiary amine N-oxide 
d . d 221 re uctlOn was propose by Kato et al. The reaction mechanism was described to 
be NADPH-dependent. Cytochrome P450 is first reduced by NADPH. The N-oxide 
is then coordinated with the reduced cytochrome haem region. After a further one 
electron reduction of the reduced cytochrome P450-N-oxide complex concomitant 
with a two electron reduction of the tertiary amine N-oxide, tertiary amine and water 
are formed as the final products. In biological systems, the electron donors in the 
cytochrome P450 mediated N-oxide reduction can be cytochrome bs, NADPH-
cytochrome P450 reductase, or other flavoproteins. 
Lignocaine N-oxide reduction via myoglobin 
Lignocaine N-oxide was reduced by deoxymyoglobin to lignocaine under anaerobic 
conditions as shown by HPLC analysis (see section 3.4.1). During this process, a 
spectral change of deoxymyoglobin [Pe(II)] to metmyoglobin [Fe(III)] was observed 
indicating that myoglobin had undergone a one electron oxidation. In anaerobic 
conditions, with no molecular oxygen to bind to the haem centre of myoglobin, the 
single oxygen from the N-oxide reduction of lignocaine N-oxide will be an alternative 
source of available oxygen. It was rationalised that a ferryl myoglobin, [F e(IV)=O or 
oxy-ferryl], intermediate should result from lignocaine-N-oxide mediated oxidation of 
myoglobin via a lignocaine-N-oxide dependent oxygen atom transfer process (see 
figure 4-1). 
Lignocaine N-oxide reduction concomitant with myoglobin oxidation was studied 
using visible spectrometry. However in the visible spectrum, the oxidation of 
deoxymyoglobin to metmyoglobin was rapid. Hence measurement of the formation of 
myoglobin oxidation intermediates, including ferryl myoglobin was not possible. In 
order to study this oxidation process further, electron spin resonance spectroscopy 
(ESR) in combination with 5,5-dimethylpyrroline 1-N-oxide (DMPO), a spin trapping 
agent for short lived free radicals222 was employed. 
A complex mixture ofESR signals comprising DMPOX (5,5-dimethylpyrrolidone-~-
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oxy-l) free radical, the oxidation product ofDMPO, 195 and DMPOI R·, a carbon 
centred radical was recorded under anaerobic conditions from deoxymyoglobin and 
lignocaine N-oxide incubated in the presence ofDMPO (see Figure 3-28 B). As 
shown in Figure 3-28, this ESR spectrum was not produced by metmyoglobin or 
lignocaine under aerobic or anaerobic conditions, and deoxymyoglobin and lignocaine 
N-oxide under aerobic conditions. These results showed that the free radical species 
produced by lignocaine N-oxide and deoxymyoglobin under anaerobic conditions did 
not come from the metmyoglobin, oxidised myoglobin [Fe(III)] or deoxymyoglobin, 
reduced myoglobin [Fe(II)] alone. However, the presence of both a DMPOI R· and 
DMPOX adduct is highly suggestive of the presence of a myoglobin [Fe(lV)=O] 
species. Such an intermediate would react with DMPO to form both DMPOX and 
DMPOI R· products. A similar ESR spectrum containing DMPOX and DMPOI R· 
was recorded from DMPO, methylamine and deoxymyoglobin under anaerobic 
conditions (see Figure 3-28 H). This result suggests that the formation of carbon 
centred radicals (DMPOI R·) may be a result of the interaction between any 
alkylamine including lignocaine N-oxide and the reduced haem of deoxymyoglobin. 
Using the ESR spectroscopy and visible spectroscopy results obtained, the proposed 
mechanism of myoglobin mediated lignocaine N-oxide reduction can be summarised 
as follows: 
1. In the absence of oxygen, deoxymyoglobin [Fe(II)=O] binds to lignocaine 
N-oxide to form a lignocaine-oxy-ferryl myoglobin [Fe(IV)=o" lignocaine ] 
intermediate. The presence of reactive oxygen species and alkyl radical 
species (trapped by DMPO as DMPOIOH and DMPOIR respectively) 
indicates that when lignocaine-N-oxide reacts with deoxymyoglobin a highly 
reactive myoglobin intermediate, such as ferryl myoglobin, is formed. DMPO 
can also be oxidised to DMPOX due to the peroxide nature of the ferryl 
intermediate. 
Deoxymyoglobin [Fe(IT)] + lignocaine N-oxide ~ 
lignocaine-oxy-ferryl myoglobin [Fe(IV)=Olignocaine] 
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2. The fonnation of metmyoglobin by lignocaine-N-oxide (as measured by 
visible spectroscopy (see figure 3-34) and the concomitant quantitative 
reduction oflignocaine-N-oxide to lignocaine (as shown by HPLC analysis, 
see figure 3-25) indicates that the ferryl myoglobin intermediate 
predominantly decomposes by loss of a hydroxyl radical-like species. This 
reactive oxygen species appears to predominantly decompose to water or by 
oxidative modification e.g. hydroxylation of myoglobin apoprotein. Such 
myoglobin oxidation products would not be detected by the spectroscopic 
methods used in this study. 
Lignocaine-oxy-ferryl myoglobin [F e(IV)=Q-"lignocaine]~ 
lignocaine + metmyoglobin [Fe(Ill)] + H20 
Enzyme kinetic constants of lignocaine N-oxide reduction in rat liver microsomes 
and heart S9 fractions 
The Km and Vmax of lignocaine N-oxide metabolism was determined in rat liver 
microsomes and rat heart S9 fractions. Similar results were obtained, with Km of 
250.0 and 269.8 ,....:M; and Vmax of 0.99 and 1.11 nmole/minlmg in the liver and heart, 
respectively. According to previous results, the mechanisms of lignocaine N-oxide 
reduction in rat liver microsomes and heart S9 fractions are both complex and 
different in the enzymes and factors involved. This similarity of the Km and V max 
can only represent similarities between lignocaine N-oxide reduction in liver 
microsomes and heart S9. It is remarkable that the kinetic attributes in the tissues are 
so similar and suggests that all the processes involved share a common rate limiting 
step. Thus may be as a result of the general requirement for haem binding of 
lignocaine N-oxide. 
Tertiary aliphatic amine as antiarrhythmic prodrugs 
The interaction of myoglobin with other tertiary amine N-oxides of antiarrhythmic 
compounds were also studied under anoxic conditions. Similar visible spectral 
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changes to those with lignocaine N-oxide were observed for the anaerobic incubation 
of amiodarone N-oxide, diltiazem N-oxide and disopyramide N-oxide with 
deoxymyoglobin. It is likely that all these N-oxides undergo a similar mechanism of 
myoglobin mediated reduction as illustrated with lignocaine N-oxide. 
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Chapter 5 Conclusions 
This study is based on a proposal concerning the feasibility of using aliphatic tertiary 
amine N-oxides as antiarrhythmic agent prodrugs. Lignocaine was selected as a 
candidate for the pro drug development because it is the drug of choice for ventricular 
arrhythmia, a condition associated with ischaemic episodes leading to regions of 
transiently hypoxic heart tissue. The present effort has been focused on the use of 
lignocaine N-oxide as a hypoxia-mediated bioreducible antiarrhythmic durg. 
Lignocaine N-oxide, a non-active and polar derivative of lignocaine, has been 
demonstrated to be activated (bioreducted) selectively in the ischaemiclhypoxic heart 
to its parent compound, lignocaine. 
A previous in vivo study of lignocaine N-oxide by McIntosh and Kane in Strathclyde 
Institute for Drug Research (1991)176 demonstrated that lignocaine N-oxide was 
biologically inert under normal conditions, but was active during ischaemia. This 
preliminary result suggested that lignocaine N-oxide might have use as a potential 
antiarrhythmic prodrug. 
In this study, the oxygen sensitivity was studied to justify whether the bioactivation of 
lignocaine N-oxide can be regulated by the prevailing oxygen tension in the target 
tissue. In a arrhythmic heart, the prodrug activation would be triggered by the 
ischaemic state of the heart and terminated as the oxygen content in the heart returned 
to a more normal level. This would therefore be expected to achieve a controlled 
release and site-specific active drug delivery. 
An HPLC method was developed to study the metabolism of lignocaine N-oxide. The 
simple and rapid method of analysis of lignocaine and its metabolites was 
demonstrated to have good reproducibility, stability and recovery. 
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5. 1 A Summary of the metabolism of lignocaine N-oxide 
It was found in this study that lignocaine N-oxide can be reduced to its active parent 
compound, lignocaine, in the absence of oxygen. No other metabolites were detected 
under anaerobic conditions. Under anaerobic conditions, no metabolism of lignocaine 
was demonstrated in rat liver microsomes and heart S9 fractions. The in vitro 
lignocaine N-oxide reduction was found to occur under anaerobic conditions in 
NADPH supplemented rat liver homogenates, microsomal suspensions~ rat heart 
homogenates, cytosolic solutions; human phenotyped cytochrome P450 isoforms~ 
purified enzymes- cytochrome P450 reductase and xanthine oxidase. 
Lignocaine N-oxide was anaerobically metabolised by the NADPHIascorbate reduced 
protohaem (haemin); and deoxymyoglobin. 
In hypoxic/anoxic isolated rat hearts, lignocaine N-oxide was found to be reduced to 
lignocaine. 
No lignocaine N-oxide reduction was found in the oxidisedlreduced inorganic iron, 
NADPH/ haem supplemented haem oxygenase and reduced haemoglobin systems 
under anaerobic conditions. 
5.1. 1 Enzymology of lignocaine N-oxide reduction 
The reduction of lignocaine N-oxide has been shown to be both enzymic and non-
enzymic. It was found that the lignocaine N-oxide reduction is NADPH dependent, 
. . db CO CN- and protein denaturation (heat). 
oxygen senSItIve and can be suppresse Y , 
It can be inhibited through the suppression ofP450 and b5 levels in rat liver 
. (. yt hrome P450 and myoglobin), non-
microsomes; mediated by haemoprotems I.e. c oc 
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haemoprotein enzymes (i.e. cytochrome P450 reductase and xanthine oxidase), or 
NADPHIascorbic acid reduced protohaem (haemin). 
According to the postulated P450 mediated N-oxide reduction mechanisms suggested 
in Figure 4-1 and the ESR study of myoglobin in section 4.3, the mechanisms of 
lignocaine N-oxide metabolism via haemoprotein can be summarised as follows: (i) 
The oxygen atom of lignocaine N-oxide is coordinated to the Fe(II) atom of the 
reduced haemoprotein. (ii) A haem[Fe(II)]-lignocaine N-oxide-protein complex is 
formed. (iii) Following the cleavage of the N-O bonding, lignocaine and an 
intermediate of an oxy-ferryl haemoprotein [oxy-Fe(IV) pair] complex is formed. 
(iv) With the release of one molecule of water, the oxidised haemoprotein [Fe(III)] is 
formed. In the P450 system, the 2 electron involved in the reduction of the 
haemoprotein in step (i) and (iv) can be provided by cytochrome b5, NADPH-
cytochrome P450 reductase (a microsomal flavinprotein), or other proteins. The 
reduction of myoglobin does not require on external electron donor due to the rapid 
oxidation of the deoxymyoglobin. 
5.1.2 Phenotyped cytochrome P450 isoforms 
Lignocaine N-oxide can be metabolised by several phenotyped human liver 
microsomes. However, there was no direct correlation between lignocaine 
N-oxidation and a panel of 12 human liver phenotyped cytochrome P450's. The 
major metabolism of lignocaine was oxidation (N-dealkylation) in human and was 
identified to be mediated by CYP3A4.209 This suggested that lignocaine N-oxide 
reduction may not be isoform specific but that lignocaine N-oxide fits the active sites 
of most cytochrome P450's. 
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5.1. 3 Other enzymes 
Three purified enzymes, NADPH-cytochrome P450 reductase, a flavin protein, 
xanthine oxidase and haem oxygenase, were examined to determine their potential of 
being an N-oxide reductase. 
Flavin proteins have been reported to be involved in the electron transfer process in 
N-oxide reduction mechanisms. 128 NADPH-cytochrome P450 reductase was 
demonstrated to have direct interaction with lignocaine N-oxide with a supplement of 
NADPH and/or haem to form lignocaine. 
Xanthine oxidase,18 which plays an important role in superoxide radical formation and 
myocardial ischaemialreperfusion injury, was capable of reducing lignocaine 
N-oxide to lignocaine under anaerobic conditions. It may be partially responsible for 
lignocaine N-oxide metabolism in the ischaemic /hypoxic heart. Whether lignocaine 
N-oxide can interact with xanthine oxidase to generate superoxide radicals during 
reperfusion was not studied and will require further investigation. 
Haem oxygenase associated with NADPH-cytochrome P450 reductase can react with 
molecular oxygen and mediates the microsomal haem degradation to bile pigments. 169 
Haem oxygenase (isoform HO-1), reported to act as mono oxygenase, failed to reduce 
lignocaine N-oxide under anaerobic conditions. 
5. 2 Lignocaine N-oxide as an antiarrhythmic prodrug 
In this study, lignocaine N-oxide was found to be a potential antiarrhythmic prodrug. 
A list of findings that support the use of lignocaine N-oxide as an antiarrhythmic 
pro drugs are as follows: 
1. The inert nature of lignocaine N-oxide as a prodrug (e.g. decreased dose-related 
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problems, such as adverse side effect and narrow therapeutical index). 
2. High recovery of lignocaine N-oxide in the urine of nonnal rats, indicating low 
metabolism of the prodrug in normal (oxic) tissues. This was based on the 
findings that: (i) no secondary metabolites of either lignocaine or lignocaine 
N-oxide were found; (ii) N-Oxidation is not a major metabolism route of 
lignocaine. 
3. Hypoxia mediated activation of lignocaine N-oxide suggesting a (disease) state-
specific controlled release of the pro drug in the hypoxic heart. Lignocaine 
N-oxide reduction was oxygen sensitive. A self-regulating mechanism of the 
pro drug release triggered by the oxygenated condition of the tissue/organ (heart) 
is proposed. 
An important but unexplained effect relating to lignocaine N-oxide reduction in the 
isolated hypoxic/anoxic rat hearts that extended the heart beating time after stopping 
the oxygen supply for up to 8 minutes, was found and requires further investigation. 
Future work 
In this study, I have demonstrated that lignocaine as well as other tertiary amine 
antiarrhythmic agents modified as N-oxides may be reduced to their active parent 
compounds under hypoxic conditions. Further experiments on lignocaine N-oxide in 
ischaemic heart animal models will provide more information concerning the activity 
of these agents in vivo. 
Previously, the pro drug approach of using aliphatic tertiary amine N-oxide as 
bioreductive anti-cancer agents has been extensively studied. 67, 68 The application of 
using aliphatic tertiary amine N-oxides as bioreductive prodrugs in ischaemia in eNS 
or other therapeutic fields have not been studied. 
The fate of orally dosed tertiary amine N-oxide (e.g. nicotine-I' -N-oxide and 
chlorpromazine N-oxide) have been studied. IB, 107 The metabolism and excretion of 
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lignocaine N-oxide though different administration routes (e.g. oral, intravenous or 
intramuscular) may require further investigation. 
The pro drug approach using lignocaine N-oxide or other N-oxide prodrugs in the 
hypoxic region besides tumour and heart can be considered. Ischaemia in chronic and 
acute wounds may be another region where a controlled-released druglprodrug 
delivery system could provide adequate site-specific treatment. 
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Appendix I Protein assay 
The protein concentration of rat liver and heart subcellular fractions was detennined 
using the Bio-Rad protein assay which is based on the observation that the absorbance 
maximum for an acidic solution of Coomassie Brilliant blue G-250 shifts from 465 
nm to 595 nm when binding to protein occurs (Riesner et ai, 19751~ Sedrnak et aI., 
19772; 3). Bovine serum albumin (BSA) was used as the protein calibration standard. 
The dye reagent, Coomassie blue, was diluted (1 : 5) with distilled water and filtered 
through Whatman filter paper (No.1) at room temperature (20-25°C). Protein 
standards (0.1-0.8 mg/ml BSA) were prepared in clean dry test tubes. The colour of 
the BSA standards was developed by addition of the dye reagent (5 ml) to aliquots of 
the BSA standards (0.1 ml) and appropriately diluted subcellular fractions (1 : 100 for 
liver microsomes). The tubes were vortex mixed and allowed standing for 10 minutes 
at room temperature. The absorbance was measured (595 run) against a dye blank 
solution. A plot of the absorbance versus the concentration of the BSA standards 
enabled the concentration of the subcellular fraction to be detennined. A typical 


















o 0.2 0.4 0.6 0.8 1 
BSA concentration (mg/ml) 
Figure A-I Bovine serum albumin (BSA) protein standard graph. 
Experimental details as described in Appendix I. 
Linear equation: Y=0.3749+0.7182X 
Correlation coefficient: FO.9909 
Appendix 
Page A-4 
Appendix II Cytochrome P450 and hs measurement 
(a) Cytochrome bs 
Ferric cytochrome b5 has a maximum absorbance at 413 run with an extinction 
coefficient of 117 mM-I em -1, while the haemoprotein is characterised by three 
distinct maxima at 424, 526 and 555 run with extinction coefficients of 171, 13.4 and 
25 6 roM I -1 . 1 4 5 . cm ,respective y' . Cytochrome b5 reduction is routinely monitored 
using wavelength pairs of 414-424 run (185 mM- I em-I), 424-500 run (130 mM-I em-I) 
and 557-567 nm (19 roMI em-I). 
The washed microsomal preparation (1.0 ml) was diluted with phosphate buffer 
(pH 7.4, 4.0 ml) to give a suspension containing 0.1 g of original liver in 1.0 ml. The 
suspension was divided between stoppered glass cuvettes as standard and samples. A 
base line was recorded between 390 and 600 nm. The contents of the sample cuvette 
were treated with sodium dithionite (about 5 mg). The difference spectrum between 
the reduced and the oxidised cytochrome b5 was recorded between 390 and 600 nm. 
The difference between the absorbance at 424 nm and that at 470 nm was measured 
and the concentration expressed as .6.424 nm-470 nmI0.5 g of original tissue. 
(b) Cytochrome P450 
The contents of both cuvettes from the cytochrome b5 determination were reduced by 
the addition of sodium dithionite (about 5 mg). The sample cuvette was treated with 
a stream of carbon monoxide for about 30 seconds. The stoppered cuvettes were 
inverted twice and the difference spectrum between the reduced cytochrome P450 
and the reduced carbon monoxide complexed material was recorded between 390 and 
600 nm. The difference between the absorbance at 450 nm and that at 490 nm was 
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